Anti-αvβ6 antibody and use thereof

By developing antibodies or antigen-binding fragments that specifically bind to integrin αvβ6, the limited efficacy of existing drugs in tumor treatment has been addressed, achieving efficient binding in the tumor microenvironment and enhancing therapeutic efficacy.

WO2026233449A1PCT designated stage Publication Date: 2026-11-12SHANGHAI HONGCHENG PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095912
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-09
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing αvβ6-targeting drugs have limited efficacy in cancer treatment, especially antibody-drug conjugates, which have low objective response rates in non-small cell lung cancer patients. There is a need to develop antibodies with more specific binding ability to the tumor microenvironment to improve treatment efficacy.

Method used

An antibody or its antigen-binding fragment that specifically binds to integrin αvβ6 has been developed, containing a specific complementary determinant region sequence variant of the heavy and light chain variable regions. This antibody can bind efficiently in the tumor microenvironment and can be conjugated to cytotoxic drugs to enhance therapeutic effects.

Benefits of technology

It achieves efficient binding of antibodies in the tumor microenvironment, significantly improving the efficacy of tumor treatment, especially the objective response rate in diseases such as non-small cell lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026095912-FTAPPB-I100001
    Figure PCTCN2026095912-FTAPPB-I100001
  • Figure PCTCN2026095912-FTAPPB-I100002
    Figure PCTCN2026095912-FTAPPB-I100002
  • Figure PCTCN2026095912-FTAPPB-I100003
    Figure PCTCN2026095912-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to the field of biomedicine, and specifically relates to an antibody or an antigen-binding fragment thereof that specifically binds to αvβ6, an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof, and the use thereof in the treatment of diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-αvβ6 antibodies and their applications Technical Field

[0001] This invention relates to the field of biomedicine, and more specifically, to antibodies that specifically bind to αvβ6 or antigen-binding fragments thereof, antibody-drug conjugates comprising said antibodies or antigen-binding fragments thereof, and their use in treating diseases. Background Technology

[0002] Integrins are α-β heterodimeric transmembrane proteins composed of 18 α subunits and 8 β subunits that randomly combine to form 24 functional integrin receptors. Widely distributed on the surface of mammalian cells, they mediate cell-cell adhesion and cell-matrix adhesion. Integrins play crucial roles in biological processes such as signal transduction, cell migration, immune responses, platelet aggregation, and tumor metastasis. Integrins have three structural conformations: "bent-closed" (inactive; dominant state), "extended-closed" (activated; low affinity or intermediate state), and "extended-open" (activated; high affinity). The integrin family can transmit extracellular environmental signals "outside-in" and regulate its own activation state "inside-out."

[0003] Integrin αvβ6, a member of the integrin family, is composed of αv and β6 subunits. αvβ6 primarily recognizes ligands containing the arginine-glycine-aspartic acid (RGD) sequence (such as transforming growth factor (TGFβ1 / 3), fibronectin, vitronectin, tenascin-C, and viral capsid proteins). Notably, β6 (ITGB6) is the rate-limiting subunit, forming a dimer only with αv; therefore, the expression and activity of αvβ6 depend on β6. Its expression level is extremely low in normal tissues, but it is significantly upregulated in various pathological states (such as fibrosis, malignant tumors, and inflammation), mainly participating in cell proliferation, adhesion, migration, and promoting physiological processes such as tissue repair and wound healing. It is particularly highly expressed in non-small cell lung cancer (NSCLC), head and neck cancer, and esophageal cancer, and is associated with poor prognosis, making it an important target for disease diagnosis and treatment.

[0004] Currently, the main types of drugs developed targeting αvβ6 include antibody-drug conjugates (ADCs), bispecific antibodies combined with immunotherapy (TCE), and blocking antibodies. Among them, Sigvotatug Vedotin (SGN-B6A) developed by Pfizer is an ADC drug targeting αvβ6, combined with the microtubule inhibitor MMAE. It is currently in Phase III clinical trials, and existing clinical data indicate that its objective response rate is 19.5% in NSCLC patients, which can be increased to 32.5% in those who have not received taxane treatment.

[0005] Therefore, existing data indicate that the development of targeted drugs, especially antibody-drug conjugates, against αvβ6 / ITGB6 has considerable efficacy and potential for cancer treatment. Summary of the Invention

[0006] Through extensive experimentation and repeated exploration, the inventors of this application obtained a monoclonal antibody that specifically binds to the ITGB6 subunit of human and monkey αvβ6. This antibody exhibits excellent tumor microenvironment-specific binding ability, and antibody-drug conjugates containing this antibody demonstrate superior tumor therapeutic effects. This completes the present invention.

[0007] Antibody or its antigen-binding fragment

[0008] On one hand, the present invention provides an antibody or antigen-binding fragment thereof that specifically binds to integrin αvβ6 (e.g., its ITGB6 subunit), comprising a heavy chain variable region (VH) and a light chain variable region (VL), and said antibody or antigen-binding fragment thereof comprises:

[0009] (1) A heavy chain variable region (VH) containing the following three complementary determinant regions (CDRs): VH CDR1 or a variant thereof as shown in SEQ ID NO:9, VH CDR2 or a variant thereof as shown in SEQ ID NO:10, and VH CDR3 or a variant thereof as shown in SEQ ID NO:11; and / or, a light chain variable region (VL) containing the following three complementary determinant regions (CDRs): VL CDR1 or a variant thereof as shown in SEQ ID NO:12, VL CDR2 or a variant thereof as shown in SEQ ID NO:13 or 29, and VL CDR3 or a variant thereof as shown in SEQ ID NO:14; or

[0010] (2) A heavy chain variable region (VH) containing the following three complementary determinant regions (CDRs): VH CDR1 or a variant thereof as shown in SEQ ID NO:1, VH CDR2 or a variant thereof as shown in SEQ ID NO:2, and VH CDR3 or a variant thereof as shown in SEQ ID NO:3; and / or a light chain variable region (VL) containing the following three complementary determinant regions (CDRs): VL CDR1 or a variant thereof as shown in SEQ ID NO:4, VL CDR2 or a variant thereof as shown in SEQ ID NO:5, and VL CDR3 or a variant thereof as shown in SEQ ID NO:6;

[0011] The variant has one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) compared to its source sequence. In some embodiments, the substitutions are conservative. In some embodiments, the CDRs (1)-(2) are defined by the Kabat numbering system.

[0012] In some embodiments, the antibody or its antigen-binding fragment comprises:

[0013] (1) A VH containing the following three complementary decision regions (CDRs): VH CDR1 as shown in SEQ ID NO:9, VH CDR2 as shown in SEQ ID NO:10, and VH CDR3 as shown in SEQ ID NO:11; and / or a VL containing the following three complementary decision regions (CDRs): VL CDR1 as shown in SEQ ID NO:12, VL CDR2 as shown in SEQ ID NO:13 or 29, and VL CDR3 as shown in SEQ ID NO:14; or

[0014] (2) A VH containing the following three complementary decision regions (CDRs): VH CDR1 as shown in SEQ ID NO:1, VH CDR2 as shown in SEQ ID NO:2, and VH CDR3 as shown in SEQ ID NO:3; and / or a VL containing the following three complementary decision regions (CDRs): VL CDR1 as shown in SEQ ID NO:4, VL CDR2 as shown in SEQ ID NO:5, and VL CDR3 as shown in SEQ ID NO:6;

[0015] The CDR is defined by the Kabat numbering system.

[0016] In some embodiments, the antibody or its antigen-binding fragment comprises:

[0017] (i) A VH containing the following three complementary determination regions (CDRs): VH CDR1, VH CDR2, and VH CDR3 contained in any of the VHs shown in SEQ ID NO: 15, 24-28; and / or a VL containing the following three complementary determination regions (CDRs): VL CDR1, VL CDR2, and VL CDR3 contained in any of the VLs shown in SEQ ID NO: 16, 30-36; or

[0018] (ii) A VH containing the following three complementary decision regions (CDRs): VH CDR1, VH CDR2 and VH CDR3 contained in the VH shown in SEQ ID NO:7; and / or a VL containing the following three complementary decision regions (CDRs): VL CDR1, VL CDR2 and VL CDR3 contained in the VL shown in SEQ ID NO:8.

[0019] In some implementations, (i)-(ii) the CDR is defined by the Kabat, IMGT or Chothia numbering system.

[0020] In some embodiments, the antibody or its antigen-binding fragment comprises a framework region sequence derived from mouse immunoglobulin.

[0021] In some embodiments, the antibody or its antigen-binding fragment contains a hot spot remove mutation. The hot spot removal includes, for example, the removal of glycosylation, isomerization, and / or deamidation sites.

[0022] In some embodiments, the antibody or its antigen-binding fragment comprises:

[0023] (1) VH or a variant thereof as shown in SEQ ID NO:15, and / or VL or a variant thereof as shown in any one of SEQ ID NO:16, 30, 31; or

[0024] (2) VH or a variant thereof as shown in SEQ ID NO:7, and / or VL or a variant thereof as shown in SEQ ID NO:8;

[0025] The variant has one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, 3, 4, or 5 amino acids) compared to its source sequence, or has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity. In some embodiments, the substitutions are conservative substitutions. In some embodiments, the variant has at least 90% sequence identity compared to its source sequence.

[0026] In some embodiments, the antibody or its antigen-binding fragment comprises:

[0027] (1) VH as shown in SEQ ID NO:15, and / or VL as shown in any one of SEQ ID NO:16, 30, or 31; or

[0028] (2) VH as shown in SEQ ID NO:7, and / or VL as shown in SEQ ID NO:8.

[0029] In some embodiments, the antibody or its antigen-binding fragment comprises:

[0030] (1) VH as shown in SEQ ID NO:15 and VL as shown in SEQ ID NO:16;

[0031] (2) VH as shown in SEQ ID NO:15 and VL as shown in SEQ ID NO:30;

[0032] (3) VH as shown in SEQ ID NO:15 and VL as shown in SEQ ID NO:31; or

[0033] (4) VH as shown in SEQ ID NO:7 and VL as shown in SEQ ID NO:8.

[0034] In some embodiments, the antibody or its antigen-binding fragment comprises a framework region sequence derived from human immunoglobulin.

[0035] In some embodiments, the antibody or its antigen-binding fragment comprises a framework region contained in the amino acid sequence encoded by a human germline antibody gene. In some embodiments, the antibody or its antigen-binding fragment comprises: a heavy chain framework region of a human heavy chain germline sequence, and / or, a light chain framework region of a human light chain germline sequence. In some embodiments, the heavy chain framework region of the human heavy chain germline sequence and / or the light chain framework region of the human light chain germline sequence may optionally contain a reversion mutation from human residues to mouse residues.

[0036] In some embodiments, the antibody or its antigen-binding fragment contains a hot spot remove mutation. The hot spot removal includes, for example, the removal of glycosylation, isomerization, and / or deamidation sites.

[0037] In some embodiments, the antibody or its antigen-binding fragment comprises:

[0038] VH or a variant thereof as shown in any of SEQ ID NO:24-28, and / or VL or a variant thereof as shown in any of SEQ ID NO:30-36;

[0039] The variant has one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, 3, 4, or 5 amino acids) compared to its source sequence, or has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity. In some embodiments, the substitutions are conservative substitutions. In some embodiments, the variant has at least 90% sequence identity compared to its source sequence.

[0040] In some embodiments, the antibody or its antigen-binding fragment comprises:

[0041] (1) VH or a variant thereof as shown in SEQ ID NO:26, and / or VL or a variant thereof as shown in SEQ ID NO:35;

[0042] (2) VH or a variant thereof as shown in SEQ ID NO:24, and / or VL or a variant thereof as shown in SEQ ID NO:32;

[0043] (3) VH or a variant thereof as shown in SEQ ID NO:25, and / or VL or a variant thereof as shown in SEQ ID NO:32;

[0044] (4) VH or a variant thereof as shown in SEQ ID NO:26, and / or VL or a variant thereof as shown in SEQ ID NO:32;

[0045] (5) VH or a variant thereof as shown in SEQ ID NO:27, and / or VL or a variant thereof as shown in SEQ ID NO:32;

[0046] (6) VH or a variant thereof as shown in SEQ ID NO:28, and / or VL or a variant thereof as shown in SEQ ID NO:32;

[0047] (7) VH or a variant thereof as shown in SEQ ID NO:24, and / or VL or a variant thereof as shown in SEQ ID NO:33;

[0048] (8) VH or a variant thereof as shown in SEQ ID NO:25, and / or VL or a variant thereof as shown in SEQ ID NO:33;

[0049] (9) VH or a variant thereof as shown in SEQ ID NO:26, and / or VL or a variant thereof as shown in SEQ ID NO:33;

[0050] (10) VH or a variant thereof as shown in SEQ ID NO:27, and / or VL or a variant thereof as shown in SEQ ID NO:33;

[0051] (11) VH or a variant thereof as shown in SEQ ID NO:28, and / or VL or a variant thereof as shown in SEQ ID NO:33;

[0052] (12) VH or a variant thereof as shown in SEQ ID NO:24, and / or VL or a variant thereof as shown in SEQ ID NO:34;

[0053] (13) VH or a variant thereof as shown in SEQ ID NO:25, and / or VL or a variant thereof as shown in SEQ ID NO:34;

[0054] (14) VH or a variant thereof as shown in SEQ ID NO:26, and / or VL or a variant thereof as shown in SEQ ID NO:34;

[0055] (15) VH or a variant thereof as shown in SEQ ID NO:27, and / or VL or a variant thereof as shown in SEQ ID NO:34;

[0056] (16) VH or a variant thereof as shown in SEQ ID NO:28, and / or VL or a variant thereof as shown in SEQ ID NO:34; or

[0057] (17) VH or a variant thereof as shown in SEQ ID NO:26, and / or VL or a variant thereof as shown in SEQ ID NO:36;

[0058] The variant has one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, 3, 4, or 5 amino acids) compared to its source sequence, or has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity. In some embodiments, the substitutions are conservative substitutions. In some embodiments, the variant has at least 90% sequence identity compared to its source sequence.

[0059] In some embodiments, the antibody or its antigen-binding fragment comprises:

[0060] (1) VH as shown in SEQ ID NO:26 and VL as shown in SEQ ID NO:35;

[0061] (2) VH as shown in SEQ ID NO:24 and VL as shown in SEQ ID NO:32;

[0062] (3) VH as shown in SEQ ID NO:25 and VL as shown in SEQ ID NO:32;

[0063] (4) VH as shown in SEQ ID NO:26 and VL as shown in SEQ ID NO:32;

[0064] (5) VH as shown in SEQ ID NO:27 and VL as shown in SEQ ID NO:32;

[0065] (6) VH as shown in SEQ ID NO:28 and VL as shown in SEQ ID NO:32;

[0066] (7) VH as shown in SEQ ID NO:24 and VL as shown in SEQ ID NO:33;

[0067] (8) VH as shown in SEQ ID NO:25 and VL as shown in SEQ ID NO:33;

[0068] (9) VH as shown in SEQ ID NO:26 and VL as shown in SEQ ID NO:33;

[0069] (10) VH as shown in SEQ ID NO:27 and VL as shown in SEQ ID NO:33;

[0070] (11) VH as shown in SEQ ID NO:28 and VL as shown in SEQ ID NO:33;

[0071] (12) VH as shown in SEQ ID NO:24 and VL as shown in SEQ ID NO:34;

[0072] (13) VH as shown in SEQ ID NO:25 and VL as shown in SEQ ID NO:34;

[0073] (14) VH as shown in SEQ ID NO:26 and VL as shown in SEQ ID NO:34;

[0074] (15) VH as shown in SEQ ID NO:27 and VL as shown in SEQ ID NO:34;

[0075] (16) VH as shown in SEQ ID NO:28 and VL as shown in SEQ ID NO:34; or

[0076] (17) VH as shown in SEQ ID NO:26 and VL as shown in SEQ ID NO:36.

[0077] In some embodiments, the antibody or its antigen-binding fragment further comprises a constant region derived from mammalian (e.g., human or mouse) immunoglobulins.

[0078] In some embodiments, the heavy chain of the antibody or its antigen-binding fragment includes a heavy chain constant region (CH) derived from human immunoglobulins (e.g., IgG, such as IgG1, IgG2, IgG3, or IgG4), and / or the light chain of the antibody or its antigen-binding fragment includes a light chain constant region (CL) derived from human immunoglobulins (e.g., κ or λ).

[0079] In some embodiments, the antibody or its antigen-binding fragment comprises the heavy chain constant region (CH) of wild-type human immunoglobulin. In some exemplary embodiments, the heavy chain constant region sequence of wild-type human immunoglobulin is shown in SEQ ID NO:17.

[0080] In some embodiments, the antibody or its antigen-binding fragment comprises the light chain constant region (CL) of wild-type human immunoglobulin. In some exemplary embodiments, the light chain constant region sequence of wild-type human immunoglobulin is shown in SEQ ID NO:19.

[0081] In some embodiments, the heavy chain of the antibody or its antigen-binding fragment contains a variant of human immunoglobulin CH, which has altered effector functions compared to wild-type human immunoglobulin CH. Functional changes can be produced by replacing at least one amino acid residue in the constant region of the antibody with a different residue or by chemical modification, for example, altering the antibody's affinity for effector ligands (such as FcR or complement C1q), thereby changing effector functions (e.g., reducing or enhancing them). The Fc region of the antibody mediates several important effector functions, such as ADCC, phagocytosis, CDC, etc.

[0082] In some embodiments, the heavy chain of the antibody or its antigen-binding fragment contains a variant of human immunoglobulin CH that has reduced or eliminated ADCC and / or CDC activity compared to wild-type human immunoglobulin CH, for example, containing mutations capable of reducing or eliminating ADCC and / or CDC activity.

[0083] In some embodiments, the heavy chain of the antibody or its antigen-binding fragment comprises CH or a variant thereof derived from human immunoglobulin IgG1, the variant having the following substitutions compared to its derived wild-type sequence: Leu234Ala and Leu235Ala (positions according to the EU numbering system). In some exemplary embodiments, the heavy chain constant region sequence of the wild-type human immunoglobulin is shown in SEQ ID NO:17, and the variant sequence of the heavy chain constant region of the wild-type human immunoglobulin is shown in SEQ ID NO:18.

[0084] In some embodiments, the antibody or its antigen-binding fragment possesses ADCC and / or CDC activity. In some embodiments, the antibody or its antigen-binding fragment possesses enhanced ADCC and / or CDC activity. In some embodiments, the heavy chain of the antibody or its antigen-binding fragment contains a variant of human immunoglobulin CH that has enhanced ADCC and / or CDC activity compared to wild-type human immunoglobulin CH, for example, by containing mutations capable of enhancing ADCC and / or CDC activity.

[0085] In some embodiments, the heavy chain of the antibody or its antigen-binding fragment comprises CH or a variant thereof derived from human immunoglobulin IgG1, the variant having the following substitutions compared to its derived wild-type sequence: Ser293Asp / Ala330Leu / Ile332Glu (position according to the EU numbering system). In some exemplary embodiments, the heavy chain constant region sequence of the wild-type human immunoglobulin is shown in SEQ ID NO:17, and the variant sequence of the heavy chain constant region of the wild-type human immunoglobulin is shown in SEQ ID NO:50.

[0086] In some embodiments, the antibody or its antigen-binding fragment comprises CH as shown in any one of SEQ ID NO:17, 18, 50 and CL as shown in SEQ ID NO:19.

[0087] In some embodiments, the antibody or antigen-binding fragment of the present invention may include post-translational modifications, such as C-terminal lysine (K) cleavage in the heavy chain, which may occur during recombinant expression in host cells (e.g., CHO cells) or during purification / storage. Therefore, in some embodiments, the heavy chain of the antibody of the present invention may contain a C-terminal lysine. In other embodiments, the heavy chain of the antibody of the present invention may also lack a C-terminal lysine.

[0088] In some embodiments, the antibody or its antigen-binding fragment comprises:

[0089] (1) A heavy chain containing the sequence shown in SEQ ID NO:41 and a light chain containing the sequence shown in SEQ ID NO:47;

[0090] (2) A heavy chain containing the sequence shown in SEQ ID NO:49 and a light chain containing the sequence shown in SEQ ID NO:47;

[0091] (3) A heavy chain containing the sequence shown in SEQ ID NO:51 and a light chain containing the sequence shown in SEQ ID NO:47;

[0092] (4) A heavy chain containing the sequence shown in SEQ ID NO:39 and a light chain containing the sequence shown in SEQ ID NO:44;

[0093] (5) A heavy chain containing the sequence shown in SEQ ID NO:40 and a light chain containing the sequence shown in SEQ ID NO:44;

[0094] (6) A heavy chain containing the sequence shown in SEQ ID NO:41 and a light chain containing the sequence shown in SEQ ID NO:44;

[0095] (7) A heavy chain containing the sequence shown in SEQ ID NO:42 and a light chain containing the sequence shown in SEQ ID NO:44;

[0096] (8) A heavy chain comprising the sequence shown in SEQ ID NO:43 and a light chain comprising the sequence shown in SEQ ID NO:44;

[0097] (9) A heavy chain containing the sequence shown in SEQ ID NO:39 and a light chain containing the sequence shown in SEQ ID NO:45;

[0098] (10) A heavy chain comprising the sequence shown in SEQ ID NO:40 and a light chain comprising the sequence shown in SEQ ID NO:45;

[0099] (11) A heavy chain containing the sequence shown in SEQ ID NO:41 and a light chain containing the sequence shown in SEQ ID NO:45;

[0100] (12) A heavy chain comprising the sequence shown in SEQ ID NO:42 and a light chain comprising the sequence shown in SEQ ID NO:45;

[0101] (13) A heavy chain containing the sequence shown in SEQ ID NO:43 and a light chain containing the sequence shown in SEQ ID NO:45;

[0102] (14) A heavy chain containing the sequence shown in SEQ ID NO:39 and a light chain containing the sequence shown in SEQ ID NO:46;

[0103] (15) A heavy chain comprising the sequence shown in SEQ ID NO:40 and a light chain comprising the sequence shown in SEQ ID NO:46;

[0104] (16) A heavy chain comprising the sequence shown in SEQ ID NO:41 and a light chain comprising the sequence shown in SEQ ID NO:46;

[0105] (17) A heavy chain comprising the sequence shown in SEQ ID NO:42 and a light chain comprising the sequence shown in SEQ ID NO:46;

[0106] (18) A heavy chain comprising the sequence shown in SEQ ID NO:43 and a light chain comprising the sequence shown in SEQ ID NO:46;

[0107] (19) A heavy chain comprising the sequence shown in SEQ ID NO:41 and a light chain comprising the sequence shown in SEQ ID NO:48;

[0108] (20) A heavy chain comprising the sequence shown in SEQ ID NO:49 and a light chain comprising the sequence shown in SEQ ID NO:44;

[0109] (21) A heavy chain comprising the sequence shown in SEQ ID NO:22 and a light chain comprising the sequence shown in SEQ ID NO:23;

[0110] (22) A heavy chain comprising the sequence shown in SEQ ID NO:22 and a light chain comprising the sequence shown in SEQ ID NO:37;

[0111] (23) A heavy chain comprising the sequence shown in SEQ ID NO:22 and a light chain comprising the sequence shown in SEQ ID NO:38; or

[0112] (24) A heavy chain containing the sequence shown in SEQ ID NO:20 and a light chain containing the sequence shown in SEQ ID NO:21.

[0113] In some embodiments, the antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, disulfide-linked Fv, scFv, di-scFv, (scFv)2, diabody, and sdAb; and / or, the antibody is a murine antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, or a multispecific antibody.

[0114] Antibody preparation

[0115] The antibodies of the present invention can be prepared by various methods known in the art, such as through genetic engineering recombination techniques. For example, DNA molecules encoding the heavy and light chain genes of the antibodies of the present invention can be obtained by chemical synthesis or PCR amplification. The resulting DNA molecules are inserted into an expression vector and then transfected into host cells. The transfected host cells are then cultured under specific conditions to express the antibodies of the present invention.

[0116] The antigen-binding fragments of the present invention can be obtained by hydrolyzing intact antibody molecules or directly from recombinant host cells. For example, the Fab' fragment can be obtained directly from host cells; the Fab' fragment can be chemically coupled to form the F(ab')2 fragment; the Fv, Fab, or F(ab')2 fragments can also be directly isolated from the recombinant host cell culture medium. Other techniques for preparing these antigen-binding fragments are fully known to those skilled in the art.

[0117] Therefore, on the other hand, the present invention also provides isolated nucleic acid molecules that encode the antibody of the present invention or its antigen-binding fragment, or its heavy chain variable region and / or light chain variable region, or its heavy chain and / or light chain.

[0118] In some embodiments, the isolated nucleic acid molecule comprises a first nucleotide sequence encoding a heavy chain or a heavy chain variable region of the antibody or antigen-binding fragment of the present invention, and a second nucleotide sequence encoding a light chain or a light chain variable region of the antibody or antigen-binding fragment of the present invention, wherein the first nucleotide sequence and the second nucleotide sequence are present on the same or different isolated nucleic acid molecules. When the first nucleotide sequence and the second nucleotide sequence are present on different isolated nucleic acid molecules, the isolated nucleic acid molecule of the present invention comprises a first nucleic acid molecule containing the first nucleotide sequence and a second nucleic acid molecule containing the second nucleotide sequence.

[0119] On the other hand, the present invention also provides a vector comprising the isolated nucleic acid molecules as described above. In some embodiments, the vector is a cloning vector or an expression vector.

[0120] In some embodiments, the vector comprises a first nucleotide sequence encoding a heavy chain or a heavy chain variable region of the antibody or antigen-binding fragment of the present invention and a second nucleotide sequence encoding a light chain or a light chain variable region of the antibody or antigen-binding fragment of the present invention, wherein the first nucleotide sequence and the second nucleotide sequence are present on the same or different vectors. When the first nucleotide sequence and the second nucleotide sequence are present on different vectors, the vector of the present invention comprises a first vector containing the first nucleotide sequence and a second vector containing the second nucleotide sequence.

[0121] On the other hand, the present invention also provides a host cell comprising the isolated nucleic acid molecules or vectors as described above.

[0122] Such host cells include, but are not limited to, prokaryotic cells such as bacterial cells (e.g., Escherichia coli cells), eukaryotic cells such as fungal cells (e.g., yeast cells), insect cells, plant cells, and animal cells (e.g., mammalian cells, such as mouse cells, human cells, etc.). In some embodiments, the host cell is a mammalian cell, such as a CHO cell.

[0123] On the other hand, the present invention also provides a method for preparing the antibody or antigen-binding fragment thereof of the present invention, comprising culturing host cells as described above under conditions that allow expression of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the cultured host cell culture.

[0124] Derived antibodies

[0125] The antibodies or antigen-binding fragments of the present invention can be derivatized, for example, by being linked to another molecule (e.g., another polypeptide or protein). Generally, derivatization (e.g., labeling) of the antibody or antigen-binding fragment does not adversely affect its binding to αvβ6. Therefore, the antibodies or antigen-binding fragments of the present invention are also intended to include such derivatized forms. For example, the antibodies or antigen-binding fragments of the present invention can be functionally linked (by chemical coupling, gene fusion, non-covalent linkage, or other means) to one or more other molecular groups, such as another antibody (e.g., forming a bispecific antibody), a detection reagent, a pharmaceutical reagent, and / or a protein or polypeptide (e.g., an avidin or a multihistidine tag) capable of mediating the binding of the antibody or antigen-binding fragment to another molecule.

[0126] On the other hand, the present invention also provides antibody-drug conjugates comprising the antibody or antigen-binding fragment thereof of the present invention and a therapeutic agent attached to said antibody or antigen-binding fragment thereof.

[0127] In some implementations, the therapeutic agent is a cytotoxic drug.

[0128] In some embodiments, the cytotoxic agent is monomethyloprestatin. In some embodiments, the cytotoxic agent is monomethyloprestatin E (MMAE).

[0129] In some embodiments, the cytotoxic agent is camptothecin or a derivative thereof. In some embodiments, the cytotoxic agent is F1012 disclosed in WO2024255740A1, which is incorporated herein by reference.

[0130] In some embodiments, the therapeutic agent is coupled to the antibody or its antigen-binding fragment via a linker. In some embodiments, the linker is a non-cleavable linker, a disulfide linker, a hydrazone linker, or a protease-cleavable linker. In some exemplary embodiments, the linker is MC-VC-PAB, wherein MC is 6-maleiminoacetyl, VC is valine-citrulline, and PAB is p-aminobenzyloxycarbonyl. In some exemplary embodiments, the linker is Py-VA, wherein Py is methanesulfonylpyrimidine, and VA is valine-alanine.

[0131] In some exemplary embodiments, the cytotoxic drug has the structure shown in FIG12, wherein: mAb is an antibody that specifically binds to integrin αvβ6 or an antigen-binding fragment thereof, and n is an integer selected from 1 to 10. In some exemplary embodiments, the average value of n (i.e., DAR value) in the population of the cytotoxic drug is 1-10, for example 2-8, 2-6, 2-5, 3-5, for example about 4.

[0132] In some exemplary embodiments, the cytotoxic drug has the structure shown in FIG10, wherein: mAb is an antibody that specifically binds to integrin αvβ6 or an antigen-binding fragment thereof, and n is an integer selected from 1 to 10. In some exemplary embodiments, the average value of n (i.e., DAR value) in the population of the cytotoxic drug is 1-10, for example 2-9, 4-9, 6-9, 7-9, for example about 8.

[0133] On the other hand, the present invention also provides bispecific or multispecific antibodies comprising the antibody of the present invention or its antigen-binding fragment. In some embodiments, the bispecific or multispecific antibody specifically binds to αvβ6 and additionally specifically binds to one or more other targets. In some embodiments, the bispecific or multispecific antibody further comprises at least one molecule (e.g., a second antibody) having a second binding specificity against a second target.

[0134] Pharmaceutical Composition

[0135] On the other hand, the present invention also provides pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof of the present invention, isolated nucleic acid molecules, a carrier, a host cell, a bispecific or multispecific antibody or antibody-drug conjugate, and pharmaceutically acceptable carriers and / or excipients.

[0136] In some embodiments, the pharmaceutical composition further comprises additional pharmaceutically active agents.

[0137] In some embodiments, the additional pharmaceutically active agent is an antitumor drug.

[0138] In some embodiments, in the pharmaceutical composition, the antibody or antigen-binding fragment thereof of the present invention, the isolated nucleic acid molecule, the carrier, the host cell, the bispecific or multispecific antibody or antibody-drug conjugate, and the additional pharmaceutically active agent may be provided as separate components or as mixed components. Therefore, the antibody or antigen-binding fragment thereof of the present invention, the isolated nucleic acid molecule, the carrier, the host cell, the bispecific or multispecific antibody or antibody-drug conjugate, and the additional pharmaceutically active agent may be administered simultaneously, separately, or sequentially.

[0139] In some embodiments, the pharmaceutical composition may include a “therapeutic effective amount” or a “preventative effective amount” of the antibody or antigen-binding fragment thereof of the present invention, an isolated nucleic acid molecule, a carrier, a host cell, a bispecific or multispecific antibody or antibody-drug conjugate. A “preventative effective amount” refers to an amount sufficient to prevent, stop, or delay the onset of disease. A “therapeutic effective amount” refers to an amount sufficient to cure or at least partially stop the disease and its complications in a patient already suffering from the disease. Therapeutic effective amounts may vary depending on factors such as the severity of the disease to be treated, the overall state of the patient’s own immune system, the patient’s general characteristics such as age, weight, and sex, the method of drug administration, and other concurrent treatments, etc.

[0140] application

[0141] Therapeutic applications

[0142] On the other hand, the present invention also provides the use of the antibodies or antigen-binding fragments thereof, isolated nucleic acid molecules, vectors, host cells, bispecific or multispecific antibodies, antibody-drug conjugates or pharmaceutical compositions of the present invention in the preparation of medicaments for the prevention and / or treatment of diseases related to αvβ6 in subjects.

[0143] In some implementations, the diseases associated with αvβ6 are selected from cancer, fibrotic diseases, and inflammation.

[0144] In some implementations, the cancer is selected from non-small cell lung cancer, bladder cancer, head and neck cancer, esophageal cancer, pharyngeal cancer, breast cancer (such as triple-negative breast cancer), or esophageal squamous cell carcinoma.

[0145] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human primate (e.g., a cynomolgus monkey).

[0146] In some embodiments, the antibody or its antigen-binding fragment, isolated nucleic acid molecule, vector, host cell, bispecific or multispecific antibody, antibody-drug conjugate may be used alone or in combination with other pharmaceutically active agents (e.g., antitumor drugs).

[0147] On the other hand, the present invention also provides a method for preventing and / or treating diseases associated with αvβ6 in subjects, the method comprising: administering to a subject in need an effective amount of an antibody of the present invention or an antigen-binding fragment thereof, an isolated nucleic acid molecule, a vector, a host cell, a bispecific or multispecific antibody, an antibody-drug conjugate, or a pharmaceutical composition.

[0148] In some embodiments, the antibody of the present invention or its antigen-binding fragment, or a pharmaceutical composition comprising said antibody or its antigen-binding fragment, is administered to a subject.

[0149] In some embodiments, the antibody-drug conjugate of the present invention or a pharmaceutical composition comprising the antibody-drug conjugate is administered to a subject.

[0150] In some implementations, the diseases associated with αvβ6 are selected from cancer, fibrotic diseases, and inflammation.

[0151] In some implementations, the cancer is selected from non-small cell lung cancer, bladder cancer, head and neck cancer, esophageal cancer, pharyngeal cancer, breast cancer (such as triple-negative breast cancer), or esophageal squamous cell carcinoma.

[0152] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human primate (e.g., a cynomolgus monkey).

[0153] In some embodiments, the antibody or its antigen-binding fragment, isolated nucleic acid molecule, vector, host cell, bispecific or multispecific antibody, antibody-drug conjugate may be used alone or in combination with other pharmaceutically active agents (e.g., antitumor drugs).

[0154] The antibodies or antigen-binding fragments thereof, isolated nucleic acid molecules, carriers, host cells, bispecific or multispecific antibodies, antibody-drug conjugates, or pharmaceutical compositions of the present invention can be formulated into any dosage form known in the medical field, such as tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injection solutions, sterile powders for injection, and concentrated solutions for injection), inhalers, sprays, etc. Preferred dosage forms depend on the intended route of administration and therapeutic use. The antibodies or antigen-binding fragments thereof, isolated nucleic acid molecules, carriers, host cells, bispecific or multispecific antibodies, antibody-drug conjugates, or pharmaceutical compositions of the present invention should be sterile and stable under the conditions of manufacture and storage. A preferred dosage form is an injection. Such injections may be sterile injectable solutions. For example, sterile injectable solutions can be prepared by incorporating the required dose of the antibody or antigen-binding fragment of the present invention, isolated nucleic acid molecules, carriers, host cells, bispecific or multispecific antibodies, antibody-drug conjugates, or pharmaceutical compositions, and optionally, simultaneously incorporating other desired components (including, but not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers, diluents, osmotic pressure maintaining agents, absorption delaying agents, preservatives, stabilizers, or any combination thereof) into a suitable solvent, followed by sterile filtration. Alternatively, sterile injectable solutions can be prepared as sterile lyophilized powders (e.g., by vacuum drying or freeze-drying) for easy storage and use. Such sterile lyophilized powders can be dispersed in a suitable carrier before use, such as water for injection (WFI), antibacterial water for injection (BWFI), sodium chloride solution (e.g., 0.9% NaCl), glucose solution (e.g., 5% glucose), solution containing surfactant (e.g., 0.01% polysorbate 20), pH buffer solution (e.g., phosphate buffer solution), Ringer's solution, and any combination thereof.

[0155] The antibodies or antigen-binding fragments thereof, isolated nucleic acid molecules, carriers, host cells, bispecific or multispecific antibodies, antibody-drug conjugates, or pharmaceutical compositions of the present invention may be administered by any suitable method known in the art, including but not limited to oral, oral, sublingual, ocular, topical, parenteral, rectal, intrathecal, intracytoplasmic reticulum groove, groin, bladder, topical (e.g., powder, ointment, or drops), or nasal routes. However, for many therapeutic uses, the preferred route of administration is parenteral (e.g., intravenous injection or bolus, subcutaneous injection, intraperitoneal injection, intramuscular injection). Those skilled in the art will understand that the route and / or method of administration will vary depending on the intended purpose. In some embodiments, the antibodies or antigen-binding fragments thereof, isolated nucleic acid molecules, carriers, host cells, bispecific or multispecific antibodies, antibody-drug conjugates, or pharmaceutical compositions of the present invention are administered by intravenous injection or bolus.

[0156] Detection Application

[0157] In another aspect, the present invention provides a method for detecting the presence or level of integrin αvβ6 in a sample, comprising the following steps:

[0158] (1) Contact the sample with the antibody or its antigen-binding fragment of the present invention;

[0159] (2) Detect the formation of a complex between the antibody or its antigen-binding fragment and integrin αvβ6 or detect the amount of the complex.

[0160] The formation of the complex indicates the presence of integrin αvβ6 or cells expressing integrin αvβ6.

[0161] In some embodiments, the integrin αvβ6 comprises an extended-open configuration. In some embodiments, the integrin αvβ6 comprises human integrin αvβ6.

[0162] In some embodiments, the antibody or antigen-binding fragment of the present invention is further labeled with a detectable marker. In other embodiments, in step (2), a reagent labeled with a detectable marker is used to detect the antibody or antigen-binding fragment of the present invention.

[0163] In some embodiments, the detectable label is selected from enzymes (e.g., horseradish peroxidase or alkaline phosphatase), chemiluminescent reagents (e.g., acrid esters, luminol and its derivatives, or ruthenium derivatives), fluorescent dyes (e.g., fluorescein or fluorescent protein), radionuclides, or biotin.

[0164] In some implementations, the method can be used for diagnostic purposes, such as when the sample is from a subject, and the presence or level of αvβ6 in the sample is detected to diagnose whether the subject has an αvβ6-related disease, such as cancer, based on the detection results.

[0165] In some implementations, the method can be used for non-diagnostic purposes, such as when the sample is not from a subject, for example, an antigen sample.

[0166] In some implementations, the subject is a mammal, such as a human or a non-human primate (e.g., a cynomolgus monkey).

[0167] On the other hand, the present invention also provides the use of antibodies or antigen-binding fragments thereof in the preparation of diagnostic reagents for detecting the presence or level of αvβ6 in a sample and / or diagnosing whether a subject has an αvβ6-related disease.

[0168] Terminology Definition

[0169] In this invention, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the operational steps used herein, such as cell culture, molecular biology, biochemistry, nucleic acid chemistry, and immunology, are all conventional steps widely used in their respective fields. To better understand this invention, definitions and explanations of relevant terms are provided below.

[0170] When the terms “for example,” “such as,” “like,” “including,” “contains,” or variations thereof are used herein, these terms will not be considered restrictive terms but will be interpreted as meaning “but not limited to” or “not limited to.”

[0171] Unless otherwise specified herein or clearly contradicted by the context, the terms “an” and “a kind” as well as “the” and similar designations shall be interpreted to cover both the singular and the plural in the context of describing the invention (especially in the context of the following claims).

[0172] As used herein, the term "αvβ6" is an integrin composed of αv and β6 (ITGB6) subunits. Its expression level is extremely low in normal tissues, but it is significantly upregulated in various pathological conditions (such as fibrosis, malignant tumors, and inflammation). It is primarily involved in physiological processes such as cell proliferation, adhesion, migration, and promoting tissue repair and wound healing. The sequence of the ITGB6 subunit of αvβ6 is well known to those skilled in the art (see, for example, NCBI GENBANK database accession number: AAI21179.1).

[0173] As used herein, the term "antibody" refers to an immunoglobulin-derived molecule capable of specifically binding to a target antigen via at least one antigen-binding site located in its variable region. When referring to the term "antibody," unless the context explicitly indicates otherwise, it includes not only the complete antibody but also antigen-binding fragments capable of specifically binding to a target antigen. A "complete antibody" typically consists of two pairs of polypeptide chains, each pair comprising one light chain (LC) and one heavy chain (HC). The antibody light chain can be classified as κ (kappa) and λ (lambda) light chains. The heavy chain can be classified as μ, δ, γ, α, or ε, and the isotypes of the antibody are defined as IgM, IgD, IgG, IgA, and IgE, respectively. Within both the light and heavy chains, the variable and constant regions are linked by a "J" region of approximately 12 or more amino acids, and the heavy chain also contains a "D" region of approximately 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The constant domain does not directly participate in antibody-antigen binding but exhibits various effector functions, such as mediating the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The VH and VL regions can be further subdivided into highly degenerated regions (called complementarity-determining regions (CDRs)) interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions (VH and VL) of each heavy chain / light chain pair form the antigen-binding sites. The distribution of amino acids in different regions or domains can follow the definitions in Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 878-883.

[0174] As used herein, the term “complementarity-determining region” or “CDR” refers to the amino acid residues in the antibody variable region responsible for antigen binding. Each of the heavy and light chain variable regions contains three CDRs, designated CDR1, CDR2, and CDR3. The precise boundaries of these CDRs can be defined according to various numbering systems known in the art, such as the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 878-883), or the IMGT numbering system (Lefranc et al., Dev. Comparat. Immunol. 27: 55-77, 2003). For a given antibody, those skilled in the art will readily identify the CDR as defined by each numbering system. Furthermore, the correspondence between different numbering systems is well known to those skilled in the art (see, for example, Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003).

[0175] In this invention, the CDR contained in the antibody or antigen-binding fragment thereof can be determined according to various numbering systems known in the art. In some embodiments, the CDR contained in the antibody or antigen-binding fragment thereof is preferably determined by the Kabat numbering system.

[0176] As used herein, the term “frame region” or “FR” residues refer to the amino acid residues in the antibody variable region other than the CDR residues as defined above.

[0177] The term "antibody" is not limited to any particular method of producing antibodies. For example, it includes recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. Antibodies can be different isotypes of antibodies, such as IgG (e.g., IgG1, IgG2, IgG3, or IgG4 subtypes), IgA1, IgA2, IgD, IgE, or IgM antibodies.

[0178] As used herein, the term “antigen-binding fragment” of an antibody refers to a polypeptide containing a fragment of the full-length antibody that retains the ability to specifically bind to the same antigen bound by the full-length antibody, and / or competes with the full-length antibody for specific binding to the antigen; it is also referred to as the “antigen-binding moiety”. See also Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Antigen-binding fragments of antibodies can be generated by recombinant DNA technology or by enzymatic or chemical cleavage of intact antibodies. Non-limiting examples of antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, disulfide-linked Fv, scFv, di-scFv, diabody, single-domain antibody, and peptides containing at least a portion of an antibody sufficient to confer specific antigen-binding ability to the peptide. Engineered antibody variants are reviewed in Holliger et al., 2005; Nat Biotechnol, 23:1126-1136.

[0179] As used herein, the term "Fd" refers to an antibody fragment consisting of VH and CH1 domains; the term "Fab fragment" refers to an antibody fragment consisting of VL, VH, CL, and CH1 domains; the term "F(ab')2 fragment" refers to an antibody fragment containing two Fab fragments linked by disulfide bridges on the hinge region; and the term "Fab' fragment" refers to the fragment obtained by reducing the disulfide bonds connecting the two heavy chain fragments in the F(ab')2 fragment, consisting of a complete light and heavy chain Fd fragment (consisting of VH and CH1 domains).

[0180] As used herein, the term "Fv" refers to an antibody fragment consisting of the VL and VH domains of a single arm of the antibody. Fv fragments are generally considered to be the smallest antibody fragment capable of forming a complete antigen-binding site. It is generally believed that six CDRs confer antigen-binding specificity to the antibody. However, even a variable region (such as an Fd fragment, which contains only three antigen-specific CDRs) can recognize and bind to the antigen, although its affinity may be lower than that of a complete binding site.

[0181] As used herein, the term "Fc" refers to an antibody fragment formed by the disulfide bonds connecting the second and third constant regions of the first heavy chain to the second and third constant regions of the second heavy chain. The Fc fragment of an antibody has a variety of functions but does not participate in antigen binding. "Effective functions" mediated by the Fc domain include Fc receptor binding; Clq binding and complement-dependent cytotoxicity (CDC); antibody-dependent cell-mediated cytotoxicity (ADCC); phage activity; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation. The Fc domain can include both native and variant Fc regions. Native Fc regions contain amino acid sequences consistent with those found in naturally occurring Fc regions, such as the native human IgG1 Fc region; the native human IgG2 Fc region; the native human IgG3 Fc region; and the native human IgG4 Fc region, as well as their naturally occurring variants. Variant Fc regions contain amino acid sequences that differ from the amino acid sequence of native Fc regions due to at least one amino acid modification. In some implementations, the variant Fc region may have altered effector functions compared to the native Fc region (e.g., Fc receptor binding, antibody glycosylation, number of cysteine ​​residues, effector cell function, or complement function).

[0182] As used herein, the term "scFv" refers to a single polypeptide chain containing VL and VH domains linked by a linker. Such scFv molecules may have a general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of a repeating GGGGS amino acid sequence or a variant thereof. For example, a linker having the amino acid sequence (GGGGS)4 can be used, but variants thereof may also be used. In some cases, a disulfide bond may also exist between the VH and VL of the scFv. In some embodiments of the invention, scFv may form di-scFv, which refers to two or more individual scFvs linked in tandem to form an antibody. In some embodiments of the invention, scFv may form (scFv)2, which refers to two or more individual scFvs linked in parallel to form an antibody.

[0183] As used herein, the term “biantibody” means that its VH and VL domains are expressed on a single polypeptide chain, but the linker is too short to allow pairing between the two domains on the same chain, thus forcing the domain to pair with the complementary domain of another chain and creating two antigen-binding sites (see, for example, Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak RJ et al., Structure 2:1121-1123 (1994)).

[0184] As used herein, the term "single-domain antibody (sdAb)" has the meaning commonly understood by those skilled in the art as referring to an antibody fragment consisting of a single monomeric variable antibody domain (e.g., a single heavy chain variable region) that maintains the ability to specifically bind the same antigen bound by a full-length antibody.

[0185] As used herein, the term "bispecific antibody" refers to an antibody that has binding specificity to two different antigens (or epitopes). The term "multispecific antibody" refers to an antibody that has binding specificity to at least two (e.g., three or four) different antigens (or epitopes). Bispecific or multispecific antibodies comprise multiple antigen-binding domains that have binding specificity to different antigens (or epitopes), thereby enabling them to bind to at least two different binding sites and / or target molecules. The individual antigen-binding domains comprised in a bispecific or multispecific antibody may be independently selected from full-length antibodies (e.g., IgG antibodies) or their antigen-binding fragments (e.g., Fv fragments, Fab fragments, F(ab')2 fragments, or scFv). In some cases, the individual antigen-binding domains are linked by peptide linkers.

[0186] Each of the above antibody fragments retains the ability to specifically bind to the same antigen bound by the full-length antibody, and / or competes with the full-length antibody for specific binding to the antigen.

[0187] Antigen-binding fragments (e.g., the antibody fragments described above) of a given antibody (e.g., the antibody provided in this invention) can be obtained using conventional techniques known to those skilled in the art (e.g., recombinant DNA techniques or enzymatic or chemical fragmentation methods), and the antigen-binding fragments of the antibody can be specifically screened in the same manner as those used for intact antibodies.

[0188] As used herein, the term "humanized antibody" refers to a genetically engineered non-human antibody whose amino acid sequence is modified to increase sequence homology with a human antibody. Typically, all or part of the CDR region of a humanized antibody is derived from a non-human antibody (donor antibody), and all or part of the non-CDR region (e.g., the variable region FR and / or constant region) is derived from a human immunoglobulin (receptor antibody). In some embodiments, the CDR region of the humanized antibody is derived from a non-human antibody (donor antibody), and all or part of the non-CDR region (e.g., the variable region FR and / or constant region) is derived from a human immunoglobulin (receptor antibody). Humanized antibodies typically retain the intended properties of the donor antibody, including but not limited to antigen specificity, affinity, reactivity, etc. In this application, the donor antibody may be a murine antibody with the intended properties (e.g., antigen specificity, affinity, reactivity, etc.). To prepare a humanized antibody, the CDR region of the donor antibody can be inserted into a human frame sequence using methods known in the art. In some cases, the human frame sequence may contain amino acid mutations substituted by corresponding non-human residues. Furthermore, the humanized antibody may also contain residues not found in either the variable region of the initial donor antibody (e.g., the light chain variable region or the heavy chain variable region) or the human frame sequence, to further improve or optimize the performance of the humanized antibody.

[0189] As used herein, the term "chimeric antibody" refers to an antibody whose light chain and / or heavy chain is derived from a portion of an antibody (which may be derived from a particular species or belong to a particular antibody class or subclass), and another portion of the light chain and / or heavy chain is derived from another antibody (which may be derived from the same or different species or belong to the same or different antibody class or subclass), but which retains its binding activity to the target antigen in any case. In some embodiments, the term "chimeric antibody" may include an antibody in which the variable regions of the heavy chain and light chain are derived from a first antibody, while the constant regions of the heavy chain and light chain are derived from a second antibody.

[0190] As used herein, the term "identity" refers to the sequence matching between two polypeptides or two nucleic acids. To determine the percentage identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., a gap may be introduced in the first amino acid sequence or nucleic acid sequence to best align with the second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecule is identical at that position. The percentage identity between two sequences is a function of the number of identity positions shared by the sequences (i.e., percentage identity = number of identical overlapping positions / total number of positions × 100%). In some embodiments, the two sequences are of the same length.

[0191] The determination of percentage identity between two sequences can also be achieved using mathematical algorithms. A non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, as an improvement upon that in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877. Such algorithms are integrated into the NBLAST and XBLAST procedures of Altschul et al., 1990, J. Mol. Biol. 215:403.

[0192] As used herein, the term "variant," in the context of polypeptides (including polypeptides), also refers to a polypeptide or peptide containing an amino acid sequence altered by the introduction of amino acid residue substitutions, deletions, or additions. In some cases, the term "variant" also refers to a polypeptide or peptide that has been modified (i.e., by covalently linking any type of molecule to the polypeptide or peptide). For example, but not limited to, polypeptides can be modified, such as by glycosylation, acetylation, polyethylene glycolation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, linking to cellular ligands or other proteins, etc. Derivatized polypeptides or peptides can be produced by chemical modification using techniques known to those skilled in the art, including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Furthermore, variants have similar, identical, or improved functions to the polypeptide or peptide from which they are derived.

[0193] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and its target antigen. The strength or affinity of a specific binding interaction can be expressed by the equilibrium dissociation constant (KD) of that interaction. In this invention, the term "KD" refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the stronger the antibody-antigen binding, and the higher the affinity between the antibody and the antigen.

[0194] The specific binding properties between two molecules can be determined using methods known in the art. One method involves measuring the rate of formation and dissociation of the antigen binding site / antigen complex. Both the “binding rate constant” (ka or kon) and the “dissociation rate constant” (kdis or koff) can be calculated from the concentration and the actual rates of association and dissociation. The ratio of kdis / kon is equal to the dissociation constant KD. The values ​​of KD, kon, and kdis can be measured using any effective method. In some embodiments, the dissociation constant can be measured in Biacore using surface plasmon resonance (SPR).

[0195] As used herein, the detectable markers described herein can be any substance detectable by fluorescent, spectroscopic, photochemical, biochemical, immunological, electrical, optical, or chemical means. Such markers are well known in the art, and examples include, but are not limited to, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, β-galactosidase, urease, glucose oxidase, etc.), radionuclides (e.g., 3H, 125I, 35S, 14C, or 32P), fluorescent dyes (e.g., fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC), fluorescent proteins (e.g., phycoerythrin (PE)), Texas red, rhodamine, quantum dots, or cyanine dye derivatives (e.g., Cy7, Alexa 750)), luminescent substances (e.g., chemiluminescent agents such as acridinium esters, luminol and its derivatives, ruthenium derivatives such as terpyridine ruthenium), and magnetic beads (e.g., The detectable label may include, for example, colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads, and biotin for binding avidin (e.g., streptavidin) modified with the aforementioned label. In some embodiments, the detectable label is selected from enzymes (e.g., horseradish peroxidase or alkaline phosphatase), chemiluminescent reagents (e.g., acrid esters, luminol and their derivatives, or ruthenium derivatives), fluorescent dyes (e.g., fluorescein or fluorescent protein), radionuclides, or biotin. In some embodiments, the detectable label described above may be linked to the antibody or its antigen-binding fragment of the present invention via linkers of varying lengths to reduce potential steric hindrance.

[0196] As used herein, the term "nucleic acid" can refer to any polymer containing deoxyribonucleotides or ribonucleotides, including but not limited to modified or unmodified DNA and RNA, without any particular limitation on their length. For nucleic acids used to construct recombinant constructs, DNA is preferred because it is more stable and easier to manipulate than RNA.

[0197] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which polynucleotides can be inserted. When a vector enables the expression of a protein encoded by the inserted polynucleotide, it is called an expression vector. Vectors can be introduced into host cells through transformation, transduction, or transfection, allowing the genetic material elements they carry to be expressed in the host cells. Vectors are well-known to those skilled in the art and include, but are not limited to: plasmids; phage particles; Cos plasmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), or P1-derived artificial chromosomes (PAC); bacteriophages such as λ phage or M13 phage; and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retrotranscriptoviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomaviruses (such as SV40). A vector may contain multiple elements controlling expression, including but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain a replication initiation site.

[0198] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells, or human cells.

[0199] As used herein, the term "conservative substitution" means an amino acid substitution that does not adversely affect or alter the intended properties of a protein / peptide containing an amino acid sequence. For example, conservative substitutions can be introduced using standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions include substitutions of amino acid residues with amino acid residues having similar side chains, such as substitutions with residues that are physically or functionally similar to the corresponding amino acid residues (e.g., having similar size, shape, charge, chemical properties, including the ability to form covalent or hydrogen bonds). Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid and glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, and tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, and methionine), β-branched side chains (e.g., threonine, valine, and isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, and histidine). Therefore, it is preferable to replace the corresponding amino acid residue with another amino acid residue from the same side chain family. Methods for identifying conserved amino acid substitutions are well known in the art (see, for example, Brummell et al., Biochem. 32:1180-1187 (1993); Kobayashi et al., Protein Eng. 12(10):879-884 (1999); and Burks et al., Proc. Natl Acad. Set USA 94:412-417 (1997), which are incorporated herein by reference).

[0200] The twenty common amino acids mentioned in this article are written in accordance with conventional usage. See, for example, Immunology-A Synthesis (2nd Edition, E.S. Golub and D.G. Ren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In this invention, the terms “polypeptide” and “protein” have the same meaning and are used interchangeably. Furthermore, in this invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0201] As used herein, the term "pharmaceutically acceptable carrier and / or excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art and includes, but is not limited to: pH adjusters, surfactants, adjuvants, ionic strength enhancers, diluents, osmotic pressure maintaining agents, absorption delay agents, preservatives, and stabilizers. For example, pH adjusters include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Osmotic pressure maintaining agents include, but are not limited to, sugars, NaCl, and their analogues. Absorption delay agents include, but are not limited to, monostearates and gelatin. Diluents include, but are not limited to, water, aqueous buffers (such as buffered saline), alcohols, and polyols (such as glycerol). Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, etc. Stabilizers have the meaning commonly understood by those skilled in the art as being able to stabilize the desired activity of an active ingredient in a drug, including but not limited to monosodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dried whey, albumin, or casein) or their degradation products (such as lactalbumin hydrolysate).

[0202] As used herein, the terms “cancer” and “tumor” are used interchangeably and refer to a broad class of diseases characterized by the uncontrolled growth of abnormal cells in the body. Uncontrolled cell division can lead to the formation of malignant tumors or cells that invade adjacent tissues and can metastasize to distant sites of the body via the lymphatic system or bloodstream. Cancer includes benign and malignant cancers, as well as dormant tumors or micrometastases. Cancer also includes hematologic malignancies.

[0203] As used herein, the term "prevention" refers to a method implemented to prevent or delay the occurrence of a disease, condition, or symptom in a subject. As used herein, the term "treatment" refers to a method implemented to achieve a beneficial or desired clinical outcome in a subject exhibiting disease symptoms or diagnosed with a disease. For the purposes of this invention, beneficial or desired clinical outcomes include (but are not limited to) alleviating symptoms, reducing the extent of the disease, stabilizing (i.e., no longer worsening) the state of the disease, delaying or slowing the progression of the disease, improving or alleviating the state of the disease, and relieving symptoms (whether partial or complete), whether detectable or undetectable. Furthermore, "treatment" can also refer to prolonged survival compared to expected survival (e.g., survival without treatment).

[0204] As used herein, the term "subject" refers to a mammal, such as a human or a non-human primate (e.g., a cynomolgus monkey). In some embodiments, the subject has cancer, or is at risk of having the aforementioned disease.

[0205] As used herein, the term "effective amount" means an amount sufficient to achieve, or at least partially achieve, the desired effect. For example, an effective amount for disease prevention means an amount sufficient to prevent, stop, or delay the onset of said disease; an effective amount for disease treatment means an amount sufficient to cure or at least partially stop the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is entirely within the capabilities of those skilled in the art. For example, an effective amount for therapeutic purposes will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general characteristics such as age, weight, and sex, the manner of administration of the drug, and other concurrent treatments, etc.

[0206] Beneficial effects of the invention

[0207] The anti-αvβ6 antibody provided by this invention has a better tumor microenvironment-specific binding ability compared with existing drugs targeting the same target, and the antibody-drug conjugate containing the antibody has excellent tumor therapeutic effects and has significant clinical value. Attached Figure Description

[0208] Figures 1A-1E: Binding activity of anti-ITGB6 chimeric antibody with SW780 cells under different conditions. Specifically, Figures 1A-1B show the binding activity of anti-ITGB6 chimeric antibody with SW780 cells under EDTA conditions; Figure 1C shows the binding activity of anti-ITGB6 chimeric antibody with SW780 cells under Ca / Mg conditions; and Figures 1D-1E show the binding activity of anti-ITGB6 chimeric antibody with SW780 cells under MnCl2 conditions.

[0209] Figures 2A-2C: Blocking activity of anti-ITGB6 chimeric antibody against LAP on SW780 cells. Figure 2A shows the blocking activity of the antibody against LAP on SW780 cells under Ca / Mg conditions; Figures 2B-2C show the blocking activity of the chimeric antibody against LAP on SW780 cells under MnCl2 conditions.

[0210] Figures 3A-3E: Binding activity of humanized M080 antibody with SW780 cells under different conditions. Specifically, Figures 3A-3B show the binding activity of humanized M080 antibody with SW780 cells under EDTA conditions; Figure 3C shows the binding activity of humanized M080 antibody with SW780 cells under Ca / Mg conditions; and Figures 3D-3E show the binding activity of humanized M080 antibody with SW780 cells under MnCl2 conditions.

[0211] Figures 4A-4C: Binding activity of humanized antibody (LALA) with SW780 cells under different conditions. Specifically, Figure 4A shows the binding activity of humanized antibody (LALA) with SW780 cells under EDTA conditions; Figure 4B shows the binding activity of humanized antibody (LALA) with SW780 cells under Ca / Mg conditions; and Figure 4C shows the binding activity of humanized antibody (LALA) with SW780 cells under MnCl2 conditions.

[0212] Figures 5A-5B: Blocking activity of humanized anti-ITGB6 antibody against ligand LAP. Figure 5A shows the LAP blocking activity of the humanized anti-ITGB6 antibody under Ca / Mg conditions; Figure 5B shows the LAP blocking activity of the humanized anti-ITGB6 antibody under MnCl2 conditions.

[0213] Figure 6A: ELISA binding activity of anti-ITGB6 humanized antibody to human αvβ6 protein.

[0214] Figure 6B: ELISA binding activity of anti-ITGB6 humanized antibody to human αvβ1 protein.

[0215] Figure 6C: ELISA binding activity of anti-ITGB6 humanized antibody to human αvβ3 protein.

[0216] Figure 6D: ELISA binding activity of anti-ITGB6 humanized antibody to human αvβ5 protein.

[0217] Figure 6E: ELISA binding activity of anti-ITGB6 humanized antibody to human αvβ8 protein.

[0218] Figure 7: Endocytotic activity of anti-ITGB6 humanized antibody on human tumor cells Calu3.

[0219] Figure 8: Anti-ITGB6 humanized antibody-induced antibody-dependent cell-mediated cytotoxicity of HEK293-hITGB6 cells against Jurkat-human FcγRⅢa(158V)-NFAT cells.

[0220] Figure 9: Antibody-dependent cell-mediated cytotoxicity of CHOK1-hITGB6 cells against Jurkat-human FcγRⅢa(158V)-NFAT cells induced by anti-ITGB6 humanized antibody.

[0221] Figure 10: Structure of anti-ITGB6 antibody conjugate with F1012.

[0222] Figure 11A: Conventional killing activity of anti-ITGB6 humanized antibody conjugate with F1012 on HEK293-hITGB6 cells.

[0223] Figure 11B: Conditional killing activity of anti-ITGB6 humanized antibody conjugate with F1012 on HEK293-hITGB6 cells (+0.25 μg / mL human Latent TGFβ1).

[0224] Figure 11C: Conventional killing activity of anti-ITGB6 humanized antibody conjugate with F1012 on BxPC3-hITGB6 cells.

[0225] Figure 11D: Conditional killing activity of anti-ITGB6 humanized antibody conjugate with F1012 on BxPC3-hITGB6 cells (+0.25 μg / mL human Latent TGFβ1).

[0226] Figure 12: Structure of anti-ITGB6 antibody conjugate with MMAE.

[0227] Figures 13A-13B: Inhibition of growth of human non-small cell lung cancer NCI-H441 subcutaneous xenograft model by anti-ITGB6 antibody conjugated with MMAE. Figure 13A shows the change in tumor volume in mice with the NCI-H441 subcutaneous xenograft model after drug administration; Figure 13B shows the change in body weight in mice with the NCI-H441 subcutaneous xenograft model after drug administration.

[0228] Figures 14A-14B: Inhibition of growth of SW780 subcutaneous xenograft tumors in immunodeficient mice using anti-ITGB6 antibody conjugated with MMAE. Figure 14A shows the change in tumor volume in the SW780 subcutaneous xenograft tumor model mice after drug administration; Figure 14B shows the change in body weight in the SW780 subcutaneous xenograft tumor model mice after drug administration.

[0229] Figures 15A-15B: Inhibition of growth of human non-small cell lung cancer NCI-H441 subcutaneous xenograft model by anti-ITGB6 antibody conjugated with F1012. Figure 15A shows the change in tumor volume in mice with the NCI-H441 subcutaneous xenograft model after drug administration; Figure 15B shows the change in body weight in mice with the NCI-H441 subcutaneous xenograft model after drug administration.

[0230] Figures 16A-16B: Inhibition of growth in a human non-small cell lung cancer Calu-3 subcutaneous xenograft model by anti-ITGB6 antibody conjugated with F1012. Figure 16A shows the change in tumor volume in the Calu-3 subcutaneous xenograft model mice after drug administration; Figure 16B shows the change in body weight in the Calu-3 subcutaneous xenograft model mice after drug administration.

[0231] Figures 17A-17B: Inhibition of growth of human poorly differentiated squamous cell esophageal cancer KYSE410 subcutaneous xenograft model by anti-ITGB6 antibody conjugated with F1012. Figure 17A shows the change in tumor volume in the KYSE410 subcutaneous xenograft model mice after drug administration; Figure 17B shows the change in body weight in the KYSE410 subcutaneous xenograft model mice after drug administration.

[0232] Figures 18A-18B: Inhibition of growth of human pharyngeal squamous cell carcinoma FADU subcutaneous xenograft model by anti-ITGB6 antibody conjugated with F1012 drug. Figure 18A shows the change in tumor volume in the FADU subcutaneous xenograft mouse model after drug administration; Figure 18B shows the change in body weight in the FADU subcutaneous xenograft mouse model after drug administration.

[0233] Sequence information

[0234] Information about the sequences involved in this invention is described in the table below:

[0235] Table 1: Sequence Description Detailed Implementation

[0236] The invention will now be described in the following non-limiting embodiments.

[0237] Those skilled in the art will understand that the embodiments are described by way of example only and are not intended to limit the scope of protection claimed in this application. Unless otherwise specified, the experimental methods in the embodiments are conventional methods. Where specific conditions are not specified in the embodiments, they are performed according to conventional conditions or conditions recommended by the manufacturer. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products.

[0238] Example 1: Immunization to obtain murine anti-ITGB6 monoclonal antibodies

[0239] 1.1 Immunization of mice and screening of hybridomas for anti-ITGB6 antibodies

[0240] To screen for antibodies that specifically bind to human and monkey ITGB6, this invention used recombinant human αvβ6-his protein (KACTUS, ITG-HM4V6) and the CHOK1 engineered cell line hITGB6-CHOK1 (GM-C29044, Jiman Biotechnology (Shanghai) Co., Ltd.) overexpressing human ITGB6 as immunogens to immunize 6-8 week old Balb / c, SJL mice (Shanghai Slack Laboratory Animal Co., Ltd.). The immune response was monitored using human αvβ6-specific binding-ELISA and FACS assays. When serum titers met requirements, mouse spleens were collected using standard methods to prepare B lymphocyte suspensions. The B lymphocyte suspensions were then electrofusiond with SP2 / 0 myeloma cells (ATCC, CRL-1581) at a ratio of 1:2 to 1:1. Clones binding to human αvβ6 and cynomolgus monkey αvβ6 proteins were screened using Binding-ELISA. Clones binding to SW780 cells (human bladder cancer cells, Nanjing Kebai Biotechnology Co., Ltd., CBP60650) and the Jurkat engineered cell line Jurkat-hITGB6 (GM-C35521, overexpressing human ITGB6) were then screened using flow cytometry (FACS) and sequenced. The variable region sequences of the finally screened murine antibodies are shown in Table 2.

[0241] Table 2: Sequence composition of the variable regions of the heavy and light chains of murine anti-ITGB6 antibodies

[0242] The CDR is determined by the Kabat scheme.

[0243] 1.2 Preparation of anti-ITGB6 chimeric antibody

[0244] Recombinant chimeric antibodies were obtained by replacing the constant region of a murine monoclonal antibody. The nucleotide sequence encoding the variable region of the murine monoclonal antibody was then cloned into a pCDNA3.1 vector (ThermoFisher, V79020) containing protein sequences encoding the human heavy chain constant region (Human IgG1, SEQ ID NO:17) and the light chain constant region (kappa, SEQ ID NO:19). After gene sequence synthesis, the cells were transfected into CHO cells (Gibco, A37785). Cells were centrifuged after 5-7 days, and the cell culture medium was collected and filtered. The harvested cell culture supernatant was loaded onto a Protein A column (MabSelect SuRe, GE). The bound antibody was eluted with glycine, the elution buffer was neutralized with 1M Tris, and the buffer was replaced with PBS to obtain the chimeric antibody.

[0245] Example 2: Functional analysis of anti-ITGB6 chimeric antibody

[0246] 2.1 Binding activity of anti-ITGB6 chimeric antibody to SW780 cells under different conditions

[0247] 2.1.1 Experimental reagents / consumables (Table 3)

[0248] 2.1.2 Experimental Design and Results

[0249] SW780 cells that have reached the exponential growth phase and are in good condition were subjected to cell digestion, centrifugation, and cell counting. The cells were then adjusted to 2×10⁻⁶ cells / mL using the following three 2x FACS conditional buffers. 6 Cells / mL: (1) 2x EDTA FACS buffer (Tris buffered saline, 2% FBS, 20mM EDTA); (2) 2x Ca / Mg FACS buffer (Tris buffered saline, 2% FBS, 2mM CaCl2, 1mM MgCl2); (3) 2x MnCl2 FACS buffer (Tris buffered saline, 2% FBS, 2mM MnCl2). 50 μL / well of SW780 cell suspension prepared with the above three buffers was added to a 96-well low-adsorption plate (Absin, Abs7060). The purified monoclonal chimeric antibody to be tested and three control antibodies (anti-human ITGB6 antibody h2A2, synthesized according to the sequence in patent US20210198367A1; anti-human ITGB6 antibody 15H3, synthesized according to the sequence in patent WO2013123152A2; and anti-human ITGB6 antibody 3G9, synthesized according to the sequence in patent US20050255102A1) were serially diluted with 1x FACS buffer (Tris-buffered saline, 2% FBS) and 50 μL / well was diluted into the above 96-well plate and incubated at 4°C for 1 hour. Cells were washed with the corresponding 1x conditional buffers: (1) 1x EDTA FACS buffer (Tris-buffered saline, 2% FBS, 10mM EDTA); (2) 1x Ca / Mg FACS buffer (Tris-buffered saline, 2% FBS, 1mM CaCl2, 0.5mM MgCl2); (3) 1x MnCl2 FACS buffer (Tris-buffered saline, 2% FBS, 1mM MnCl2). After washing three times, 100 μL of secondary antibody Alexa Fluor 647 goat anti-human IgG (Jackson, 109-605-008) dilution was added to each well to resuspend the cells, and the cells were incubated at 4°C for about 45 minutes. Following the same washing process, cells were washed three times with the corresponding 1x conditional buffer. After the last wash, 85 μL of the corresponding 1x conditional buffer was added to each well to resuspend the cells, and the cells were analyzed by flow cytometry (BECKMAN COULTER cytoFLEX or BD FACSCelesta). TMThe mean fluorescence intensity (MFI) was read, and the data was analyzed using Graphpad Prism 8.0 software. The logarithm of antibody concentration was plotted on the x-axis, and the corresponding MFI value on the y-axis. A four-parameter regression model was used to fit the antibody dose-response curve, and the EC50 was calculated. 50 .

[0250] The results are shown in Figures 1A-1E and Tables 4-5. Only the control antibody 3G9 bound to SW780 cells under EDTA conditions, while the chimeric antibodies M078 and M080, along with the control antibodies h2A2 and 15H3, showed almost no binding to SW780 cells under EDTA conditions (Figures 1A-1B). Under Ca / Mg conditions (Figure 1C), the control antibodies h2A2, 15H3, and 3G9 maintained binding to SW780 cells, while the chimeric antibody M080 showed only weak binding activity to SW780 cells. Under MnCl2 conditions (Figures 1D-1E), the control antibodies h2A2, 15H3, and 3G9, as well as the chimeric antibodies M078 and M080, all showed good binding activity to SW780 cells. This invention modulates the conformational morphology of αvβ6 in vitro under different ionic conditions, and current results indicate that M080 binds more preferentially to the active conformation of αvβ6 in the tumor microenvironment.

[0251] Table 4: ECGs of the binding activity of anti-ITGB6 chimeric antibody (M078) to SW780 under different conditions 50

[0252] N / A: Not applicable, no valid EC obtained. 50 .

[0253] Table 5: EC5 values ​​of binding activity of anti-ITGB6 chimeric antibody (M080) to SW780 under different conditions 50

[0254] N / A: Not applicable, no valid EC obtained. 50 .

[0255] 2.2 Blocking activity of anti-ITGB6 chimeric antibody against ligand LAP

[0256] 2.2.1 Experimental reagents and consumables (Table 6)

[0257] 2.2.2 Experimental Design and Results

[0258] SW780 cells that have reached the exponential growth phase and are in good condition were digested, centrifuged, and counted. The cells were then adjusted to 2×10⁶ cells using the following two 2x FACS conditional buffers.6 Cells / mL: (1) 2x Ca / Mg FACS buffer (Tris buffered saline, 2% FBS, 2mM CaCl2, 1mM MgCl2); (2) 2x MnCl2 FACS buffer (Tris buffered saline, 2% FBS, 2mM MnCl2). Take 50 μL / well of SW780 cell suspension prepared with the above two buffers and add it to a 96-well low-adsorption plate (Absin, Abs7060). After serially diluting the purified monoclonal chimeric antibody to be tested and 3 control antibodies (same as in Example 2.1) with 1x FACS buffer (Tris buffered saline, 2% FBS), take 50 μL / well and dilute it into the above 96-well plate. After incubating at 4°C for 45 minutes, add LAP (to a final concentration of 1 μg / mL) and incubate at 4°C for 45 minutes. Cells were washed with the corresponding 1x conditional buffers: (1) 1x Ca / Mg FACS buffer (Tris-buffered saline, 2% FBS, 1mM CaCl2, 0.5mM MgCl2); (2) 1x MnCl2 FACS buffer (Tris-buffered saline, 2% FBS, 1mM MnCl2). After washing three times, the cells were resuspended in a dilution of the secondary antibody Alexa Fluor 647 goat anti-human IgG (Jackson, 109-605-008) and incubated at 4°C for about 45 minutes. The same washing process was repeated three times with the corresponding 1x conditional buffer. After the last wash, 85 μL of the corresponding 1x conditional buffer was added to each well to resuspend the cells. The cells were then analyzed by flow cytometry (BECKMAN COULTER cytoFLEX or BD FACSCelesta). TM The mean fluorescence intensity (MFI) was read, and the data was analyzed using Graphpad Prism 8.0 software. The logarithm of antibody concentration was plotted on the x-axis, and the corresponding MFI value on the y-axis. A four-parameter regression model was used to fit the antibody dose-response curve, and the EC50 was calculated. 50 .

[0259] The results are shown in Figures 2A-2C and Tables 6 and 7. Under Ca / Mg conditions (Figure 2A), control antibodies 15H3 and 3G9 showed strong blocking activity against LAP in SW780 cells, while control antibody h2A2 showed weak blocking activity. The chimeric antibody M080 showed weaker blocking activity against LAP than control antibody h2A2. Under MnCl2 conditions (Figures 2B-2C), control antibodies 15H3 and 3G9 and chimeric antibody M078 were strong blocking antibodies against LAP; control antibody h2A2 and chimeric antibody M080 were both partial blocking antibodies against LAP. These results suggest that the antibodies of the present invention effectively block LAP, with M080 weakly blocking the signaling pathway, avoiding the related toxicity caused by strong interference with the physiological function of αvβ6.

[0260] Table 6: IC50 of the chimeric antibody (M080) against LAP 50

[0261] N / A: Not applicable, no valid IC was obtained. 50 .

[0262] Table 7: IC50 of the blocking activity of chimeric antibody (M078) against LAP 50

[0263] N / A: Not applicable, no valid IC was obtained. 50 .

[0264] Example 3: Humanization of mouse anti-ITGB6 antibody

[0265] By comparing the germline gene database of heavy and light chain variable regions of human antibodies with MOE software, germline genes of heavy and light chain variable regions with high homology to murine antibodies were selected as templates. The CDRs of murine antibodies were transplanted into the corresponding human templates to form variable region sequences in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. As needed, key amino acids in the backbone sequence were reverted to their corresponding amino acids from the murine antibody to maintain the original affinity. Hot spots (glycosylation, isomerization, and deamidation sites) were removed through mutation, thus obtaining the humanized anti-ITGB6 monoclonal antibody. The amino acid residues in the CDR region were determined and annotated using the Kabat numbering system. Based on the results of Example 2, the hybridoma human-mouse chimeric antibody M080 was selected for humanization.

[0266] (1) Selection of humanized architecture for M080

[0267] The humanized light chain template for M080 is Homsap IGKV1-39 IGKV1-39*1JK2 V-KAPPA, and the humanized heavy chain template is IGHV3-23 IGHV3-23*1 JH6 VH. After humanization, the humanized antibody hM080 is obtained. The humanized variable region sequence is shown in Table 8 below.

[0268] Table 8: Sequence composition of the heavy and light chain variable regions of the ITGB6 humanized antibody hM080

[0269] (2) Hot spot removal and reversion mutation design were performed on the humanized variable region obtained in (1), as shown in Table 9 below.

[0270] Table 9: hM080 Hot spot removal and recovery mutation design Note: N82AS indicates that the N at position 82A has been mutated back to S according to the Kabat numbering system. Grafted means that the mouse antibody CDR has been implanted into the human FR region sequence.

[0271] (3) Combine the heavy chain sequence and light chain sequence obtained in (2) to obtain mutants M080-1 and M080-2 of anti-ITGB6 antibody M080, and mutants of anti-ITGB6 humanized antibody hM080. The specific sequence combinations are shown in Table 10 below.

[0272] Table 10: Mutant sequence combinations of anti-ITGB6 antibodies and their humanized antibodies

[0273] (4) The variable region sequences of the antibodies obtained after hot spot removal and reverse mutation of M080 and hM080 are shown in Tables 11 and 12 below.

[0274] Table 11: Combinations of heavy and light chain variable regions of anti-ITGB6 antibodies and their humanized antibodies

[0275] Table 12: Sequence composition of the variable regions of heavy and light chains of anti-ITGB6 antibodies and their humanized antibodies

[0276] Example 4: In vitro activity evaluation of humanized anti-ITGB6 antibody

[0277] 4.1 Binding activity of humanized anti-ITGB6 antibody to SW780 cells under different conditions

[0278] 4.1.1 Binding activity of humanized M080 molecules with SW780 cells under different conditions

[0279] Using the experimental method described in Example 2.1, humanized antibodies were screened by detecting the binding activity of humanized M080 molecules with SW780 cells under different conditions. Based on the experimental results (Figures 3A-3E), corresponding ECGs were fitted. 50 The values ​​are shown in Table 13. The selected humanized antibody and the maternal mouse chimeric antibody M080 showed comparable binding levels to SW780 cells under different conditions. Binding on SW780 cells under EDTA conditions was weak (Figures 3A-3B), while binding under Ca / Mg conditions (Figure 3C) and MnCl2 conditions (Figures 3D-3E) was similar to that of the maternal mouse chimeric antibody M080. These results suggest that the humanized antibody maintained the conformational bias of the maternal antibody M080 towards the αvβ6 active form in the tumor microenvironment.

[0280] Table 13: EC5 activity of humanized M080 antibody binding to SW780 cells under different conditions 50 (nM) or Top MFI Note: " / ": Not detected; N / A: Not applicable, no valid EC was obtained. 50 .

[0281] 4.1.2 Binding activity of humanized M080 molecule (LALA) with SW780 cells under different conditions

[0282] The heavy chain constant region of humanized M080 molecules (hM080-3, hM080-3EG) was mutated by LALA (sequence shown in SEQ ID NO:18) to obtain antibodies hM080-3-LALA and hM080-3EG-LALA, the sequences of which are shown in Table 14 below.

[0283] Table 14: Sequence composition of humanized anti-ITGB6 antibody (LALA)

[0284] The binding activity of the humanized anti-ITGB6 antibody (LALA) on SW780 cells was verified as in Example 2.1, and the experimental results are shown in Figures 4A-4C. The corresponding ECGs were fitted. 50 Alternatively, the TOP MFI values ​​are shown in Table 15. The results suggest that the humanized antibody with the LALA mutation maintained the bias of the maternal antibody toward the αvβ6 active conformation in the tumor microenvironment.

[0285] Table 15: EC5 binding of humanized antibody (LALA) to SW780 cells under different conditions 50 Or Top MFI

[0286] 4.2 Determination of the affinity between humanized antibodies and human αVβ6 protein and cynomolgus monkey αVβ6 protein

[0287] 4.2.1 Experimental reagents / consumables (Table 16)

[0288] 4.2.2 Experimental Design and Results

[0289] The affinity of antibodies for human αvβ6 and cynomolgus monkey αvβ6 was detected using a ForteBio Octet (sartorius, model: R96e). Each antibody was captured using an AHC2 sensor at a capture height of approximately 1 nm, followed by the injection of human αvβ6 and cynomolgus monkey αvβ6. The human αvβ6 and cynomolgus monkey αvβ6 antigens were diluted using 1×TBS + 0.02% Tween 20 + 0.1% BSA + 1mM manganese chloride buffer, with antigen concentrations ranging from 1.56 nM to 100 nM, and a zero concentration point was set. Glycine 1.5 was used as the regeneration buffer. After the run, the data were analyzed using Octet Analysis Studio software according to the "1:1 binding kinetics fit model" to fit the binding kinetic parameters of each antibody to human αvβ6 and cynomolgus monkey αvβ6.

[0290] The binding kinetics of humanized antibodies to human αvβ6 protein are shown in Table 17. The binding kinetics of the preferred humanized molecules hM080-3 and hM080-3EG to human αvβ6 protein are comparable to or close to those of the parental M080.

[0291] The binding kinetics of humanized antibodies to cynomolgus αvβ6 protein are shown in Table 18. The binding kinetics of the preferred humanized molecules hM080-3 and hM080-3EG to cynomolgus αvβ6 protein are comparable to or close to those of the parental M080. Furthermore, the binding kinetics of hM080-3 and hM080-3EG to both human and cynomolgus αvβ6 proteins are comparable.

[0292] Table 17: Binding kinetic parameters of humanized antibodies to human αvβ6

[0293] Table 18: Binding kinetic parameters of humanized antibody to cynomolgus monkey αvβ6

[0294] 4.3 Blocking activity of humanized antibodies against ligand LAP

[0295] The blocking activity of the humanized anti-ITGB6 antibody against the ligand LAP was detected using the method described in Example 2.2. The fitted curves of the blocking activity are shown in Figures 5A and 5B, and the corresponding IC50 values ​​are shown. 50 The values ​​are shown in Table 19. Under Ca / Mg conditions (Figure 5A) or MnCl2 conditions (Figure 5B), the humanized antibodies hM080-3 and hM080-3EG are both LAP partially blocking antibodies.

[0296] Table 19: Blocking activity of humanized anti-ITGB6 antibody against LAP Note: N / A: Not applicable, no valid EC was obtained. 50 .

[0297] 4.4 Specific binding of humanized antibodies

[0298] 4.4.1 Experimental reagents and consumables (Table 20)

[0299] 4.4.2 Experimental Design and Results

[0300] The specific binding activity of the anti-human ITGB6 humanized antibody to human αvβ6, and the non-specific binding activity with human αvβ1, αvβ3, αvβ5, and αvβ8 were detected by enzyme-linked immunosorbent assay (ELISA). Highly adsorbed 96-well ELISA plates were coated with human αvβ1 protein (ACROBiosystems, IT5-H52E1), human αvβ3 protein (ACROBiosystems, IT5-H52E3), human αvβ5 protein (ACROBiosystems, IT5-H52W5), human αvβ8 protein (ACROBiosystems, IT5-H52W4), and human αvβ6 protein (KACTUS, ITG-HM4V6) and incubated overnight at 4°C. On the second day, after washing three times with 0.05% TBST (Tris-buffered saline, 0.05% Tween-20, 1mM MnCl2), the cells were blocked with 1% BSA-TBST (Tris-buffered saline, 1% BSA, 0.05% Tween-20, 1mM MnCl2) blocking buffer at 37°C for 2 hours. 100 μL of a serially diluted antibody solution prepared with 1% BSA-TBST was added to each well, and the cells were incubated at 37°C for 1.5 hours. After washing three times with 0.05% TBST, 100 μL of a secondary antibody prepared with 1% BSA-TBST (goat anti-human IgG (HRP), Abcam, Ab97225) was added to each well, and the cells were incubated at 37°C for 45 minutes. After washing three times with 0.05% TBST, TMB was used for color development (Biopanda, TBS-S-003). After stopping with 1N H2SO4, the absorbance at 450nm was measured using a microplate reader, and the OD450 value was fitted using a four-parameter model. As shown in Figures 6A-6E, compared with the systemic control antibody Abituzumab (anti-human integrin αV antibody, synthesized according to the sequence in patent US8562986B2), all detected anti-ITGB6 humanized antibodies specifically bound only to human αvβ6 protein, and there was no obvious non-specific binding with human αvβ1, αvβ3, αvβ5, or αvβ8 proteins.

[0301] 4.5 Endocytotic activity of humanized antibodies

[0302] 4.5.1 Experimental reagents and consumables (Table 21)

[0303] 4.5.2 Experimental Design and Results

[0304] The endocytic activity of human ITGB6-modified human tumor cells Calu3, naturally expressing human ανβ6, was detected. Calu3 cells were obtained by TrypLE digestion, collected by centrifugation, and resuspended in FACS buffer (1×TBS containing 2% FBS and 1 mM MnCl2). Cells were counted using a cell counter and diluted to 2×10⁻⁶ cells with FACS buffer. 6 Cell density of cells / mL. 50 μL of 2 × 10⁻⁶ cells per well. 6 Calu3 cells / mL were added to 96-well round-bottom plates with low adsorption, followed by 50 μL / well of FACS buffer diluted test sample (to a final concentration of 100 nM). The plates were incubated at 4°C for 60 minutes. After washing twice with FACS buffer, Calu3 cells were resuspended in 100 μL / well of MEM complete medium (containing 10% FBS, 1% MEM NEAA, 1% Sodium Pyruvate, and 1% Pen Strep) containing 1 mM MnCl2. Cells were then incubated at 4°C or 37°C for 0 min, 15 min, 30 min, 1 h, and 2 h, respectively. After incubation, cells were fixed with 4% PFA and temporarily stored at 4°C. After all incubation and fixation were completed, the cells were centrifuged, the supernatant was discarded, and the plates were washed twice with FACS buffer. 100 μL / well of FACS buffer diluted secondary antibody (Alexa) was added. 647 Cells were resuspended in F(ab')2Fragment Goat Anti-Human IgG (Fcγfragment specific) and incubated at 4°C for 45 minutes. After washing twice with FACS buffer, 100 μL of FACS buffer was added to each well to resuspend the cells. Fluorescence signals were collected on a flow cytometer, and the endocytosis rate (%) was calculated. As shown in Figure 7 and Table 22, the anti-ITGB6 humanized antibody hM080-3EG showed only weak endocytosis on Calu3 cells incubated at 4°C, with an endocytosis rate of 31% after 2 hours; while on Calu3 cells incubated at 37°C, hM080-3EG showed rapid endocytosis, with an endocytosis rate as high as 95% after 2 hours, indicating that hM080-3EG has highly efficient endocytic activity.

[0305] Table 22: Internalization rate (%) of anti-ITGB6 humanized antibody on human tumor cells Calu3

[0306] 4.6 Humanized antibodies induce antibody-dependent cell-mediated cytotoxicity (ADCC)

[0307] 4.6.1 Experimental reagents and consumables (Table 23)

[0308] 4.6.2 Experimental Design and Results

[0309] The One-Lite Luciferase Assay kit was used to detect antibody-dependent cell-mediated cytotoxicity (ADCC) induced by anti-hITGB6 humanized Fc modified antibody (hM080-3EG-DLE, obtained based on hM080-3EG molecule and modified Fc sequence, its heavy chain sequence is shown in SEQ ID NO:51, and its light chain sequence is shown in SEQ ID NO:47) on HEK293-hITGB6 or CHOK1-hITGB6 cells against Jurkat-human FcγRⅢa(158V)-NFAT cells. Human IgG1 Fc modified antibody (hIgG1-DLE) was used as a negative control antibody, and anti-human ITGB6 antibodies h2A2 and 3G9 Fc modified antibodies (h2A2-DLE, 3G9-DLE) were used as positive control antibodies. All antibodies used in the experiment underwent DLE modification of the Fc, and the modified Fc sequences are shown in SEQ ID NO:50 in Table 1. HEK293-hITGB6 or CHOK1-hITGB6 cells were digested with TrypLE Express and resuspended in RPMI-1640 containing 10% FBS. The cell density was adjusted to 6e5 / mL, and 50 μL was added to each well of a 96-well plate. Jurkat-human FcγRⅢa(158V)-NFAT cells were digested with TrypLE Express and resuspended in RPMI-1640 containing 10% FBS. The cell density was adjusted to 6e6 / mL, and 25 μL was added to each well of a 96-well plate. Then, 25 μL of the detection sample antibody diluted with RPMI-1640 containing 10% FBS (final concentration 10 nM) was added to each well. After mixing, the cells were incubated overnight at 37°C in a 5% CO2 incubator. The next day, 50 μL of One-Lite working solution equilibrated to room temperature was added to each well of the cell culture plate, and the plate was incubated at room temperature for 10 minutes. Ten minutes later, the 96-well plate was placed in a microplate reader to read the Luminescence signal value. The final concentration of the detected sample was used as the x-axis, and the Luminescence signal value as the y-axis for four-parameter fitting analysis. The results are shown in Figures 8 and 9 and Table 24. Compared with the negative control hIgG1-DLE, the detection antibodies induced antibody-dependent cell-mediated cytotoxicity (ADCC) in HEK293-hITGB6 or CHOK1-hITGB6 cells against Jurkat-human FcγRⅢa(158V)-NFAT cells.

[0310] Table 24: Mean RLU values ​​for assessing the activity of HEK293-hITGB6 or CHOK1-hITGB6 induced by anti-ITGB6 humanized antibody against Jurkat-human FcγRⅢa(158V)-NFAT antibody ADCC

[0311] 4.7 In vitro tumor cell killing activity of humanized antibody-conjugated F1012 drug

[0312] 4.7.1 Experimental reagents and consumables (Table 25)

[0313] 4.7.2 Experimental Design and Results

[0314] Antibodies (anti-ITGB6 humanized antibody, anti-ITGB6 control antibody h2A2, and negative control hIgG1) and PBS buffer were added to bring the antibody concentration to approximately 5 mg / mL. 10 equivalents of TCEP (Thermo, 20490) were added for reduction, and the mixture was gently shaken at 37°C for 2 hours. The temperature of the mixer was then adjusted to approximately 25°C to cool the reaction solution. 12 equivalents of F1012 dissolved in DMSO (synthesized according to the method in patent WO2024255740A1) were added, and the reaction was incubated overnight at 25°C. Finally, the reaction solution was transferred to a 30K ultrafiltration tube, and the medium was replaced 10 DV*3 times with 10 mM, pH 6.0 histidine hydrochloric acid solution. The solution was concentrated to a suitable volume, centrifuged to obtain the purified ADC product, yielding the antibody-F1012 conjugate. The structure of the ITGB6 antibody-F1012 conjugate is shown in Figure 10.

[0315] Cell Viability Detection Reagent reagent and HEK293-hITGB6 and BxPC3-hITGB6 cells overexpressing human ITGB6 were used to detect the killing activity of anti-ITGB6 humanized antibody conjugate with F1012, the same target antibody control h2A2 conjugate with F1012, and the negative control hIgG1 conjugate with F1012 against tumor cells under different conditions.

[0316] HEK293-hITGB6 and BxPC3-hITGB6 cells were obtained by TrypLE digestion and resuspended in DMEM medium containing 10% FBS. After calculating the cell density using a cell counter, HEK293-hITGB6 and BxPC3-hITGB6 cells were diluted with different media: (1) Conventional medium: DMEM medium containing 10% FBS was diluted to a density of 6×10⁻⁶ cells. 3 and 1.5×10 4(1) Cells / mL; (2) Conditioned culture medium: DMEM medium containing 0.25 μg / mL human Latent TGFβ1 and 10% FBS was diluted to densities of 6×10³ and 1.5×10³, respectively. 4 Cell viability detection reagent was added at a rate of 100 μL / well to a 96-well cell culture plate. The cell culture plate was incubated overnight at 37°C with 5% CO2. 20 μL of serially diluted ADC (anti-ADC) in DMEM medium containing 10% FBS was added to each well (5-fold serial dilution), with the last well reserved as a blank control without ADC. The 96-well cell culture plate was incubated at 37°C with 5% CO2 for 6 days. After incubation, Cell Viability Detection reagent was added to the 96-well cell culture plate and reacted at room temperature for 10 minutes. The 96-well cell culture plate was placed in a multi-mode microplate reader to read the Luminescence signal value. The data was then analyzed using GraphPad Prism 8 software, with the final concentration of the detected sample on the x-axis and cell viability (%) on the y-axis. As shown in Figures 11A-11D and Table 26, under different culture conditions, hM080-3EG-F1012 exhibited differentiated killing activity against HEK293-hITGB6 and BxPC3-hITGB6. Conditional culture conditions containing Latent TGFβ1 significantly enhanced the killing activity of hM080-3EG-F1012 against tumor cells, while the control h2A2-F1012 and the negative control hIgG1-F1012 did not show this differentiated killing activity.

[0317] Table 26: Cell-killing activity IC50 of anti-ITGB6 humanized antibody conjugate with F1012 50 (nM)

[0318] Example 5: In vivo study of ITGB6 humanized antibody

[0319] 5.1 Preparation of anti-ITGB6 antibody conjugates with MMAE or F1012

[0320] Add antibody and PBS buffer to achieve an antibody concentration of approximately 5 mg / mL. Add 2–3 equivalents of TCEP (Thermo, 20490) for reduction, and incubate at 37°C with gentle shaking for 2 hours. Then adjust the mixer temperature to approximately 25°C, cool the reaction mixture, and add 6 equivalents of MC-VC-PAB-MMAE (MCE, HY-15575) dissolved in DMSO. Incubate at 25°C for 1–2 hours. Finally, transfer the reaction mixture to a 30K ultrafiltration tube and replace the medium with 10 mM, pH 6.0 histidine hydrochloride solution at 10 DV*3. Concentrate to a suitable volume, centrifuge to obtain the purified ADC product, and determine the concentration and DAR value (as shown in Table 27). The antibody-MMAE conjugate is obtained. The structure of the ITGB6 antibody-MMAE conjugate is shown in Figure 12.

[0321] Table 27: DAR values ​​of ITGB6 humanized antibody conjugated with MMAE

[0322] The conjugate of ITGB6 antibody and F1012 was prepared according to the method in Example 4.6.2, and the concentration and DAR value were detected (as shown in Table 28).

[0323] Table 28: DAR values ​​of anti-ITGB6 antibody conjugated with F1012

[0324] 5.2 Anti-ITGB6 antibody conjugated with MMAE drug inhibits the growth of human non-small cell lung cancer NCI-H441 subcutaneous xenograft model

[0325] An NCI-H441 (human non-small cell lung cancer tumor cells) animal model was established using immunodeficient mice (SCID Beige, Vital Rivers Beijing, strain number: 405), and the antitumor efficacy of anti-ITGB6 antibody conjugated with MMAE molecule in this model was detected. 5 × 10 6 One NCI-H441 cell was resuspended in RPMI 1640 medium and mixed with an equal volume of Matrigel (catalog number: 354234, BD), and seeded subcutaneously into the right oblique rib area of ​​scid-Beige mice at a volume of 200 μL / mouse. When the average tumor volume reached approximately 200 mm², the cells were inoculated. 3 Mice were randomly divided into groups of five based on tumor volume and body weight. On the day of grouping, each animal received a single intravenous injection (iv) via tail vein at a dose of 10 mL / kg. Following grouping, the tumor's major and minor diameters were measured twice weekly using calipers (500-151-30, Mitutoyo), and tumor volume was calculated. The formula for calculating tumor volume is: Tumor volume = 0.5 × major diameter × minor diameter. 2 Animal weight should be measured twice a week during the administration period.

[0326] Efficacy evaluation: Tumor volume inhibition rate (TGITV): TGI TV (%) = [1-(T) i -T0) / (C i -C0)]×100%(T i T0: Mean tumor volume on day i of treatment; C: Mean tumor volume on day 0 of treatment. i Ci: mean tumor volume of the control group on day i of drug administration; C0: mean tumor volume of the control group on day 0 of drug administration.

[0327] As shown in Figures 13A-13B and Table 29, under the experimental conditions, the humanized anti-ITGB6 antibody hM080-3EG conjugated with MMAE exhibited a better tumor inhibition rate, with efficacy superior to the control antibodies h2A2 and 15H3. Animal weight remained stable after administration, with no significant toxicity. The control antibody h2A2 is the antibody fraction of Sigvotatug Vedotin (SGN-B6A), an ADC drug targeting αvβ6 developed by Pfizer (Seagen). This demonstrates that the antibody of this invention achieved significant, advantageous, and unexpected technical effects.

[0328] Table 29: Tumor inhibition rate of anti-ITGB6 antibody-drug conjugate MMAE in human non-small cell lung cancer NCI-H441 subcutaneous xenograft model

[0329] 5.3 Anti-ITGB6 antibody conjugated with MMAE drug inhibits the growth of human bladder cancer cell subcutaneous xenograft model SW780.

[0330] An SW780 (human bladder cancer cell) animal model was established using immunodeficient mice (Balb / c nude, Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd., strain number: D000521) to detect the antitumor efficacy of anti-ITGB6 antibody conjugated with MMAE molecule in this model. 5 × 10 6 One SW780 cell was resuspended in DMEM medium and mixed with an equal volume of Matrigel (catalog number: 354234, BD), and seeded subcutaneously into the right oblique rib area of ​​Balb / c nude mice at a volume of 200 μL / mouse. When the average tumor volume reached approximately 150 mm², the cells were inoculated. 3 Mice were randomly assigned to groups of five based on tumor volume and body weight. On the day of grouping, each animal received a single intravenous (iv) administration of 10 mL / kg via tail vein. Following grouping, the tumor's major and minor diameters were measured twice weekly using calipers (500-151-30, Mitutoyo), and tumor volume was calculated. The tumor volume calculation formula is: Tumor volume = 0.5 × major diameter × minor diameter 2Animal weight should be measured twice a week during the administration period.

[0331] Drug efficacy evaluation: Tumor volume inhibition rate (TGI) TV ): TGI TV (%) = [1-(T) i -T0) / (C i -C0)]×100%(T i T0: Mean tumor volume on day i of treatment; C: Mean tumor volume on day 0 of treatment. i Ci: mean tumor volume of the control group on day i of drug administration; C0: mean tumor volume of the control group on day 0 of drug administration.

[0332] As shown in Figures 14A-14B and Table 30, under the experimental conditions, the humanized anti-ITGB6 antibody hM080-3EG conjugated with MMAE showed good tumor inhibition rates, and its efficacy was superior to the control antibodies h2A2 and 15H3. Animal weight remained stable after administration, with no significant toxicity.

[0333] Table 30: Tumor inhibition rate of anti-ITGB6 antibody-drug conjugate MMAE in human SW780 subcutaneous xenograft model of bladder cancer cells

[0334] 5.4 Anti-ITGB6 antibody conjugated with F1012 drug inhibits the growth of human non-small cell lung cancer NCI-H441 subcutaneous xenograft model

[0335] An NCI-H441 (human non-small cell lung cancer tumor cells) animal model was established using immunodeficient mice (SCID Beige, Vital Rivers Beijing, strain number: 405), and the antitumor efficacy of anti-ITGB6 antibody conjugated with MMAE molecule in this model was detected. 5 × 10 6 One NCI-H441 cell was resuspended in RPMI 1640 medium and mixed with an equal volume of Matrigel (catalog number: 354234, BD), and seeded subcutaneously into the right oblique rib area of ​​scid-Beige mice at a volume of 200 μL / mouse. When the average tumor volume reached approximately 200 mm², the cells were inoculated. 3 Mice were randomly divided into groups of five based on tumor volume and body weight. On the day of grouping, each animal received a single intravenous injection (iv) via tail vein at a dose of 10 mL / kg. Following grouping, the tumor's major and minor diameters were measured twice weekly using calipers (500-151-30, Mitutoyo), and tumor volume was calculated. The formula for calculating tumor volume is: Tumor volume = 0.5 × major diameter × minor diameter. 2 Animal weight should be measured twice a week during the administration period.

[0336] Drug efficacy evaluation: Tumor volume inhibition rate (TGI) TV ): TGI TV (%) = [1-(T) i -T0) / (C i -C0)]×100%(T i T0: Mean tumor volume on day i of treatment; C: Mean tumor volume on day 0 of treatment. i Ci: mean tumor volume of the control group on day i of drug administration; C0: mean tumor volume of the control group on day 0 of drug administration.

[0337] As shown in Figures 15A-15B and Table 31, under the experimental conditions, the humanized anti-ITGB6 antibody hM080 conjugated with F1012 exhibited a good and dose-dependent tumor inhibition rate. Animal weight remained stable after administration, with no significant toxicity.

[0338] Table 31: Tumor inhibition rate of anti-ITGB6 antibody-drug conjugate F1012 in human non-small cell lung cancer NCI-H441 subcutaneous xenograft model

[0339] 5.5 Anti-ITGB6 antibody conjugated with F1012 drug inhibits the growth of a human non-small cell lung cancer Calu-3 subcutaneous xenograft model.

[0340] A Calu-3 (human non-small cell lung cancer tumor cells) animal model was established using immunodeficient mice (Balb / c nude, Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd., strain number: D000521) to detect the antitumor efficacy of anti-ITGB6 antibody conjugated with F1012 molecule in this model. 1×10 6 Calu-3 cells were resuspended in MEM medium and mixed with an equal volume of Matrigel (catalog number: 354234, BD), and then subcutaneously seeded at a volume of 200 μL per mouse into the right oblique rib area of ​​Balb / c nude mice. When the average tumor volume reached approximately 180 mm², the cells were inoculated. 3 Mice were randomly divided into groups of five based on tumor volume and body weight. On the day of grouping, each animal received a single intravenous injection (iv) via tail vein at a dose of 10 mL / kg. Following grouping, the tumor's major and minor diameters were measured twice weekly using calipers (500-151-30, Mitutoyo), and tumor volume was calculated. The formula for calculating tumor volume is: Tumor volume = 0.5 × major diameter × minor diameter. 2 Animal weight should be measured twice a week during the administration period.

[0341] Drug efficacy evaluation: Tumor volume inhibition rate (TGI) TV ): TGI TV(%) = [1-(T) i -T0) / (C i -C0)]×100%(T i T0: Mean tumor volume on day i of treatment; C: Mean tumor volume on day 0 of treatment. i Ci: mean tumor volume of the control group on day i of drug administration; C0: mean tumor volume of the control group on day 0 of drug administration.

[0342] As shown in Figures 16A-16B and Table 32, under the experimental conditions, the humanized anti-ITGB6 antibody hM080 conjugated with F1012 exhibited a good and dose-dependent tumor inhibition rate. Animal weight remained stable after administration, with no significant toxicity.

[0343] Table 32: Tumor inhibition rate of anti-ITGB6 antibody-drug conjugate F1012 in human non-small cell lung cancer Calu-3 subcutaneous xenograft model

[0344] 5.6 Anti-ITGB6 antibody conjugated with F1012 drug inhibits the growth of a human poorly differentiated squamous cell esophageal cancer KYSE410 subcutaneous xenograft model.

[0345] An immunodeficient mouse model of KYSE410 (human poorly differentiated squamous esophageal carcinoma cells) was established using NOD SCID mice (Zhejiang Vital River Laboratory Animal Technology Co., Ltd., strain number: 406), and the antitumor efficacy of anti-ITGB6 antibody conjugated with F1012 molecule in this model was detected. 6 × 10 6 One KYSE410 cell was resuspended in RPMI 1640 medium and seeded subcutaneously into the right oblique rib area of ​​NOD SCID mice at a volume of 100 μL / mouse. When the average tumor volume reached approximately 175 mm², the cells were inoculated. 3 Mice were randomly divided into groups of eight based on tumor volume and body weight. On the day of grouping, each animal received a single intravenous injection (iv) via tail vein at a dose of 10 mL / kg. Following grouping, the tumor's major and minor diameters were measured twice weekly using calipers (500-151-30, Mitutoyo), and tumor volume was calculated. The formula for calculating tumor volume is: Tumor volume = 0.5 × major diameter × minor diameter. 2 Animal weight should be measured twice a week during the administration period.

[0346] Drug efficacy evaluation: Tumor volume inhibition rate (TGI) TV ): TGI TV (%) = [1-(T) i -T0) / (C i -C0)]×100%(T iT0: Mean tumor volume on day i of treatment; C: Mean tumor volume on day 0 of treatment. i Ci: mean tumor volume of the control group on day i of drug administration; C0: mean tumor volume of the control group on day 0 of drug administration.

[0347] As shown in Figures 17A-17B and Table 33, under the experimental conditions, the humanized anti-ITGB6 antibody hM080 conjugated with F1012 exhibited a good and dose-dependent tumor inhibition rate. Animal weight was maintained after administration, and no significant toxicity was observed.

[0348] Table 33: Tumor inhibition rate of anti-ITGB6 antibody conjugated with F1012 drug in human poorly differentiated squamous cell esophageal cancer KYSE410 subcutaneous xenograft model

[0349] 5.7 Anti-ITGB6 antibody conjugated with F1012 drug inhibits the growth of human pharyngeal squamous cell FADU subcutaneous xenograft model.

[0350] A FADU (human pharyngeal squamous cell tumor) animal model was established using immunodeficient mice (BALB / c-Nude, Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd., strain number: D000521) and the antitumor efficacy of anti-ITGB6 antibody conjugated with F1012 molecule in this model was detected. 4×10 6 One FADU cell was resuspended in MEM medium and mixed with an equal volume of Matrigel (catalog number: 354234, BD), and seeded subcutaneously into the right oblique rib area of ​​BALB / c-Nude mice at a volume of 200 μL / mouse. When the average tumor volume reached approximately 153 mm², the cells were inoculated. 3 Mice were randomly divided into groups of eight based on tumor volume and body weight. On the day of grouping, each animal received the drug via tail vein injection (iv) at a dose of 10 mL / kg, administered once a week for a total of two weeks. After grouping, the long and short diameters of the tumor were measured twice weekly using calipers (500-151-30, Mitutoyo), and the tumor volume was calculated. The formula for calculating tumor volume is: Tumor volume = 0.5 × long diameter × short diameter 2 Animal weight should be measured twice a week during the administration period.

[0351] Drug efficacy evaluation: Tumor volume inhibition rate (TGI) TV ): TGI TV (%) = [1-(T) i -T0) / (C i -C0)]×100%(Ti: mean tumor volume in the treatment group on day i of administration, T0: mean tumor volume in the treatment group on day 0 of administration; C iCi: mean tumor volume of the control group on day i of drug administration; C0: mean tumor volume of the control group on day 0 of drug administration.

[0352] As shown in Figures 18A-18B and Table 34, under the experimental conditions, the humanized anti-ITGB6 antibody hM080 conjugated with F1012 exhibited a good and dose-dependent tumor inhibition rate. Animal weight remained stable after administration, with no significant toxicity.

[0353] Table 34: Tumor inhibition rate of anti-ITGB6 antibody conjugated with F1012 drug in human pharyngeal squamous cell carcinoma FADU subcutaneous xenograft model

[0354] Although specific embodiments of the invention have been described in detail, those skilled in the art will understand that various modifications and variations can be made to the details based on all the published teachings, and all such changes are within the scope of protection of the invention. The full scope of the invention is given by the appended claims and any equivalents thereof.

Claims

1. An antibody or antigen-binding fragment thereof that specifically binds to integrin αvβ6, comprising: (1) A heavy chain variable region (VH) containing the following three complementary determinant regions (CDRs): VH CDR1 or a variant thereof as shown in SEQ ID NO:9, VH CDR2 or a variant thereof as shown in SEQ ID NO:10, and VH CDR3 or a variant thereof as shown in SEQ ID NO:11; and / or, a light chain variable region (VL) containing the following three complementary determinant regions (CDRs): VL CDR1 or a variant thereof as shown in SEQ ID NO:12, VL CDR2 or a variant thereof as shown in SEQ ID NO:13 or 29, and VL CDR3 or a variant thereof as shown in SEQ ID NO:14; or (2) A heavy chain variable region (VH) containing the following three complementary determinant regions (CDRs): VH CDR1 or a variant thereof as shown in SEQ ID NO:1, VH CDR2 or a variant thereof as shown in SEQ ID NO:2, and VH CDR3 or a variant thereof as shown in SEQ ID NO:3; and / or, a light chain variable region (VL) containing the following three complementary determinant regions (CDRs): VL CDR1 or a variant thereof as shown in SEQ ID NO:4, VL CDR2 or a variant thereof as shown in SEQ ID NO:5, and VL CDR3 or a variant thereof as shown in SEQ ID NO:6; wherein, The variant has one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) compared to the sequence from which it originates; preferably, the substitutions are conservative substitutions.

2. The antibody or antigen-binding fragment thereof according to claim 1, comprising: (1)(a) A VH containing the following three complementary decision regions (CDRs): VH CDR1 as shown in SEQ ID NO:9, VH CDR2 as shown in SEQ ID NO:10, and VH CDR3 as shown in SEQ ID NO:11; and / or a VL containing the following three complementary decision regions (CDRs): VL CDR1 as shown in SEQ ID NO:12, VL CDR2 as shown in SEQ ID NO:13 or 29, and VL CDR3 as shown in SEQ ID NO:14; or (b) A VH containing the following three complementary decision regions (CDRs): VH CDR1, VH CDR2, and VH CDR3 contained in a VH as shown in any one of SEQ ID NO:15, 24-28; and / or a VL containing the following three complementary decision regions (CDRs): VL CDR1, VL CDR2, and VL CDR3 contained in a VL as shown in any one of SEQ ID NO:16, 30-36. CDR3; or (2)(a) A VH containing the following three complementary decision regions (CDRs): VH CDR1 as shown in SEQ ID NO:1, VH CDR2 as shown in SEQ ID NO:2, and VH CDR3 as shown in SEQ ID NO:3; and / or a VL containing the following three complementary decision regions (CDRs): VL CDR1 as shown in SEQ ID NO:4, VL CDR2 as shown in SEQ ID NO:5, and VL CDR3 as shown in SEQ ID NO:6; or (b) A VH containing the following three complementary decision regions (CDRs): VH CDR1, VH CDR2, and VH CDR3 contained in the VH shown in SEQ ID NO:7; and / or a VL containing the following three complementary decision regions (CDRs): VL CDR1, VL CDR2, and VL CDR3 contained in the VL shown in SEQ ID NO:

8.

3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, comprising: (1) VH or a variant thereof as shown in SEQ ID NO:15, and / or VL or a variant thereof as shown in any one of SEQ ID NO:16, 30, 31; or (2) VH or a variant thereof as shown in SEQ ID NO:7, and / or VL or a variant thereof as shown in SEQ ID NO:8; in, The variant has one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, 3, 4, or 5 amino acids) compared to its source sequence, or has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; preferably, the substitutions are conservative substitutions; Preferably, the antibody or its antigen-binding fragment comprises: (1) VH as shown in SEQ ID NO:15 and VL as shown in SEQ ID NO:16; (2) VH as shown in SEQ ID NO:15 and VL as shown in SEQ ID NO:30; (3) VH as shown in SEQ ID NO:15 and VL as shown in SEQ ID NO:31; or (4) VH as shown in SEQ ID NO:7 and VL as shown in SEQ ID NO:

8.

4. The antibody or antigen-binding fragment thereof according to claim 1 or 2, comprising a framework region sequence derived from human immunoglobulin; Preferably, the antibody or its antigen-binding fragment comprises: a heavy chain framework region of a human heavy chain germline sequence, and / or, a light chain framework region of a human light chain germline sequence.

5. The antibody or antigen-binding fragment thereof according to claim 4, comprising: VH or a variant thereof as shown in any of SEQ ID NO:24-28, and / or VL or a variant thereof as shown in any of SEQ ID NO:30-36; in, The variant has one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, 3, 4, or 5 amino acids) compared to its source sequence, or has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; preferably, the substitutions are conservative substitutions; Preferably, the antibody or its antigen-binding fragment comprises: (1) VH as shown in SEQ ID NO:26 and VL as shown in SEQ ID NO:35; (2) VH as shown in SEQ ID NO:24 and VL as shown in SEQ ID NO:32; (3) VH as shown in SEQ ID NO:25 and VL as shown in SEQ ID NO:32; (4) VH as shown in SEQ ID NO:26 and VL as shown in SEQ ID NO:32; (5) VH as shown in SEQ ID NO:27 and VL as shown in SEQ ID NO:32; (6) VH as shown in SEQ ID NO:28 and VL as shown in SEQ ID NO:32; (7) VH as shown in SEQ ID NO:24 and VL as shown in SEQ ID NO:33; (8) VH as shown in SEQ ID NO:25 and VL as shown in SEQ ID NO:33; (9) VH as shown in SEQ ID NO:26 and VL as shown in SEQ ID NO:33; (10) VH as shown in SEQ ID NO:27 and VL as shown in SEQ ID NO:33; (11) VH as shown in SEQ ID NO:28 and VL as shown in SEQ ID NO:33; (12) VH as shown in SEQ ID NO:24 and VL as shown in SEQ ID NO:34; (13) VH as shown in SEQ ID NO:25 and VL as shown in SEQ ID NO:34; (14) VH as shown in SEQ ID NO:26 and VL as shown in SEQ ID NO:34; (15) VH as shown in SEQ ID NO:27 and VL as shown in SEQ ID NO:34; (16) VH as shown in SEQ ID NO:28 and VL as shown in SEQ ID NO:34; or (17) VH as shown in SEQ ID NO:26 and VL as shown in SEQ ID NO:

36.

6. The antibody or antigen-binding fragment thereof according to any one of claims 1-5, wherein, The antibody or its antigen-binding fragment further comprises a constant region derived from mammalian (e.g., human or mouse) immunoglobulins; Preferably, the heavy chain of the antibody or its antigen-binding fragment includes a heavy chain constant region (CH) derived from human immunoglobulins (e.g., IgG, such as IgG1, IgG2, IgG3, or IgG4), and / or the light chain of the antibody or its antigen-binding fragment includes a light chain constant region (CL) derived from human immunoglobulins (e.g., κ or λ). Preferably, the heavy chain of the antibody or its antigen-binding fragment contains a variant of human immunoglobulin CH, which has reduced or eliminated ADCC and / or CDC activity compared to wild-type human immunoglobulin CH. Preferably, the heavy chain of the antibody or its antigen-binding fragment comprises CH or a variant thereof derived from human immunoglobulin IgG1, the variant having the following substitutions compared to its derived wild-type sequence: Leu234Ala and Leu235Ala (according to the EU numbering system). Preferably, the heavy chain of the antibody or its antigen-binding fragment contains a variant of human immunoglobulin CH, which has enhanced ADCC and / or CDC activity compared to wild-type human immunoglobulin CH; Preferably, the heavy chain of the antibody or its antigen-binding fragment comprises CH or a variant of human immunoglobulin IgG1, the variant having the following substitutions compared to its derived wild-type sequence: Ser293Asp / Ala330Leu / Ile332Glu (according to the EU numbering system position); Preferably, the antibody or its antigen-binding fragment comprises CH as shown in any one of SEQ ID NO:17, 18, 50 and CL as shown in SEQ ID NO:

19.

7. The antibody or antigen-binding fragment thereof according to claim 6, wherein, The antibody or its antigen-binding fragment comprises: (1) A heavy chain containing the sequence shown in SEQ ID NO:41 and a light chain containing the sequence shown in SEQ ID NO:47; (2) A heavy chain containing the sequence shown in SEQ ID NO:49 and a light chain containing the sequence shown in SEQ ID NO:47; (3) A heavy chain containing the sequence shown in SEQ ID NO:51 and a light chain containing the sequence shown in SEQ ID NO:47; (4) A heavy chain containing the sequence shown in SEQ ID NO:39 and a light chain containing the sequence shown in SEQ ID NO:44; (5) A heavy chain containing the sequence shown in SEQ ID NO:40 and a light chain containing the sequence shown in SEQ ID NO:44; (6) A heavy chain containing the sequence shown in SEQ ID NO:41 and a light chain containing the sequence shown in SEQ ID NO:44; (7) A heavy chain containing the sequence shown in SEQ ID NO:42 and a light chain containing the sequence shown in SEQ ID NO:44; (8) A heavy chain comprising the sequence shown in SEQ ID NO:43 and a light chain comprising the sequence shown in SEQ ID NO:44; (9) A heavy chain containing the sequence shown in SEQ ID NO:39 and a light chain containing the sequence shown in SEQ ID NO:45; (10) A heavy chain comprising the sequence shown in SEQ ID NO:40 and a light chain comprising the sequence shown in SEQ ID NO:45; (11) A heavy chain containing the sequence shown in SEQ ID NO:41 and a light chain containing the sequence shown in SEQ ID NO:45; (12) A heavy chain comprising the sequence shown in SEQ ID NO:42 and a light chain comprising the sequence shown in SEQ ID NO:45; (13) A heavy chain containing the sequence shown in SEQ ID NO:43 and a light chain containing the sequence shown in SEQ ID NO:45; (14) A heavy chain containing the sequence shown in SEQ ID NO:39 and a light chain containing the sequence shown in SEQ ID NO:46; (15) A heavy chain comprising the sequence shown in SEQ ID NO:40 and a light chain comprising the sequence shown in SEQ ID NO:46; (16) A heavy chain comprising the sequence shown in SEQ ID NO:41 and a light chain comprising the sequence shown in SEQ ID NO:46; (17) A heavy chain comprising the sequence shown in SEQ ID NO:42 and a light chain comprising the sequence shown in SEQ ID NO:46; (18) A heavy chain comprising the sequence shown in SEQ ID NO:43 and a light chain comprising the sequence shown in SEQ ID NO:46; (19) A heavy chain comprising the sequence shown in SEQ ID NO:41 and a light chain comprising the sequence shown in SEQ ID NO:48; (20) A heavy chain comprising the sequence shown in SEQ ID NO:49 and a light chain comprising the sequence shown in SEQ ID NO:44; (21) A heavy chain comprising the sequence shown in SEQ ID NO:22 and a light chain comprising the sequence shown in SEQ ID NO:23; (22) A heavy chain comprising the sequence shown in SEQ ID NO:22 and a light chain comprising the sequence shown in SEQ ID NO:37; (23) A heavy chain comprising the sequence shown in SEQ ID NO:22 and a light chain comprising the sequence shown in SEQ ID NO:38; or (24) A heavy chain containing the sequence shown in SEQ ID NO:20 and a light chain containing the sequence shown in SEQ ID NO:

21.

8. The antibody or antigen-binding fragment thereof according to any one of claims 1-7, wherein, The antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, disulfide-linked Fv, scFv, di-scFv, (scFv)2, diabody, and sdAb; and / or, the antibody is a murine antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, or a multispecific antibody.

9. An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof as described in any one of claims 1-8, or a variable region of its heavy chain and / or a variable region of its light chain, or its heavy chain and / or light chain.

10. A vector comprising the isolated nucleic acid molecule of claim 9.

11. A host cell comprising the isolated nucleic acid molecule of claim 9 or the vector of claim 10.

12. A method for preparing the antibody or antigen-binding fragment thereof according to any one of claims 1-8, comprising culturing the host cell of claim 11 under conditions allowing expression of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the cultured host cell culture.

13. A bispecific or multispecific antibody comprising the antibody or antigen-binding fragment thereof as described in any one of claims 1-8; Preferably, the bispecific or multispecific antibody specifically binds to αvβ6 and additionally specifically binds to one or more other targets; Preferably, the bispecific or multispecific antibody further comprises at least one molecule (e.g., a second antibody) having a second binding specificity against a second target.

14. An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof as described in any one of claims 1-8 and a therapeutic agent conjugated thereto; Preferably, the therapeutic agent is a cytotoxic drug; Preferably, the cytotoxic drug is monomethylolpropionate, such as MMAE; Preferably, the cytotoxic drug is camptothecin or a derivative thereof, such as F1012; Preferably, the therapeutic agent is coupled to the antibody or its antigen-binding fragment via a connector; Preferably, the connector is MC-VC-PAB, wherein MC is 6-maleiminoacetyl, VC is valine-citrulline, and PAB is p-aminobenzyloxycarbonyl. Preferably, the connector is Py-VA, wherein Py is methanesulfonylpyrimidine and VA is valine-alanine; Preferably, the cytotoxic drug has the structure shown in Figure 10, wherein: mAb is an antibody that specifically binds to integrin αvβ6 or its antigen-binding fragment, and n is an integer selected from 1 to 10; Preferably, the cytotoxic drug has the structure shown in Figure 12, wherein: mAb is an antibody that specifically binds to integrin αvβ6 or its antigen-binding fragment, and n is an integer selected from 1 to 10.

15. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to any one of claims 1-8, an isolated nucleic acid molecule according to claim 9, a carrier according to claim 10, a host cell according to claim 11, a bispecific or multispecific antibody according to claim 13 or an antibody-drug conjugate according to claim 14, and a pharmaceutically acceptable carrier and / or excipient. Preferably, the pharmaceutical composition further comprises additional pharmaceutically active agents; Preferably, the additional pharmaceutically active agent is an antitumor drug.

16. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1-8, the isolated nucleic acid molecule according to claim 9, the vector according to claim 10, the host cell according to claim 11, the bispecific or multispecific antibody according to claim 13, the antibody-drug conjugate according to claim 14, or the pharmaceutical composition according to claim 15 in the preparation of a medicament for the prevention and / or treatment of αvβ6-related diseases in a subject; Preferably, the diseases associated with αvβ6 are selected from cancer, fibrotic diseases, and inflammation; Preferably, the cancer is selected from non-small cell lung cancer, bladder cancer, head and neck cancer, esophageal cancer, pharyngeal cancer, breast cancer (such as triple-negative breast cancer) or esophageal squamous cell carcinoma; Preferably, the subject is a mammal, such as a human; Preferably, the antibody or its antigen-binding fragment, isolated nucleic acid molecule, carrier, host cell, bispecific or multispecific antibody, antibody-drug conjugate, or pharmaceutical composition is used alone or in combination with other pharmaceutically active agents (e.g., antitumor drugs).

17. A method for preventing and / or treating αvβ6-related diseases in subjects, the method comprising: Administer to a subject in need an effective amount of the antibody or antigen-binding fragment of any one of claims 1-8, the isolated nucleic acid molecule of claim 9, the vector of claim 10, the host cell of claim 11, the bispecific or multispecific antibody of claim 13, the antibody-drug conjugate of claim 14, or the pharmaceutical composition of claim 15; Preferably, the diseases associated with αvβ6 are selected from cancer, fibrotic diseases, and inflammation; Preferably, the cancer is selected from non-small cell lung cancer, bladder cancer, head and neck cancer, esophageal cancer, pharyngeal cancer, breast cancer (such as triple-negative breast cancer) or esophageal squamous cell carcinoma; Preferably, the subject is a mammal, such as a human; Preferably, the antibody or its antigen-binding fragment, isolated nucleic acid molecule, carrier, host cell, bispecific or multispecific antibody, antibody-drug conjugate, or pharmaceutical composition is used alone or in combination with other pharmaceutically active agents (e.g., antitumor drugs).

18. A method for detecting the presence or level of integrin αvβ6 in a sample, comprising the following steps: (1) Contact the sample with the antibody or antigen-binding fragment thereof as described in any one of claims 1-8; (2) Detect the formation of antigen-antibody complexes or detect the amount of said complexes; Preferably, the antibody or its antigen-binding fragment further carries a detectable label; Preferably, in step (2), a reagent with a detectable label is used to detect the antibody or its antigen-binding fragment.